<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10222661</article-id><article-id pub-id-type="pmcid-ver">PMC10222661.1</article-id><article-id pub-id-type="pmcaid">10222661</article-id><article-id pub-id-type="pmcaiid">10222661</article-id><article-id pub-id-type="pmid">37242591</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15051349</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-01349</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9488-8404</contrib-id><name name-style="western"><surname>Feng</surname><given-names initials="YX">Ya-Xiu</given-names></name><xref rid="af1-pharmaceutics-15-01349" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="H">Huan</given-names></name><xref rid="af1-pharmaceutics-15-01349" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wong</surname><given-names initials="YY">Yu-Yuen</given-names></name><xref rid="af1-pharmaceutics-15-01349" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8986-3571</contrib-id><name name-style="western"><surname>Yao</surname><given-names initials="X">Xi</given-names></name><xref rid="af1-pharmaceutics-15-01349" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-15-01349" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="ML">Ming-Liang</given-names></name><xref rid="af1-pharmaceutics-15-01349" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01349" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-15-01349" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Hinrichs</surname><given-names initials="WLJ">Wouter L. J.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-01349"><label>1</label>Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong SAR, China; <email>yxfeng5-c@my.cityu.edu.hk</email> (Y.-X.F.); <email>huanhu4-c@my.cityu.edu.hk</email> (H.H.); <email>yuywong5-c@my.cityu.edu.hk</email> (Y.-Y.W.)</aff><aff id="af2-pharmaceutics-15-01349"><label>2</label>CityU Shenzhen Research Institute, Shenzhen 518071, China</aff><author-notes><corresp id="c1-pharmaceutics-15-01349"><label>*</label>Correspondence: <email>xi.yao@cityu.edu.hk</email> (X.Y.); <email>mlhe7788@gmail.com</email> (M.-L.H.); Tel.: +852-34424492 (X.Y.); +852-34424829 (M.-L.H.)</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><volume>15</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">436800</issue-id><elocation-id>1349</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>23</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-21 19:25:16.080"><day>21</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-01349.pdf"/><abstract><p>Vaccination is an effective measure to prevent infectious diseases. Protective immunity is induced when the immune system is exposed to a vaccine formulation with appropriate immunogenicity. However, traditional injection vaccination is always accompanied by fear and severe pain. As an emerging vaccine delivery tool, microneedles overcome the problems associated with routine needle vaccination, which can effectively deliver vaccines rich in antigen-presenting cells (APCs) to the epidermis and dermis painlessly, inducing a strong immune response. In addition, microneedles have the advantages of avoiding cold chain storage and have the flexibility of self-operation, which can solve the logistics and delivery obstacles of vaccines, covering the vaccination of the special population more easily and conveniently. Examples include people in rural areas with restricted vaccine storage facilities and medical professionals, elderly and disabled people with limited mobility, infants and young children afraid of pain. Currently, in the late stage of fighting against COVID-19, the main task is to increase the coverage of vaccines, especially for special populations. To address this challenge, microneedle-based vaccines have great potential to increase global vaccination rates and save many lives. This review describes the current progress of microneedles as a vaccine delivery system and its prospects in achieving mass vaccination against SARS-CoV-2.</p></abstract><kwd-group><kwd>immune response</kwd><kwd>microneedles</kwd><kwd>mass vaccination</kwd><kwd>SARS-CoV-2 vaccine</kwd><kwd>vaccine delivery</kwd></kwd-group><funding-group><award-group><funding-source>The Science Technology and Innovation Committee of Shenzhen Municipality</funding-source><award-id>JCYJ20180507181627057</award-id></award-group><award-group><funding-source>RGC General Research Fund of Hong Kong Special Administrative Region</funding-source><award-id>11104020</award-id></award-group><award-group><funding-source>Strategic Funds from City University of Hong Kong</funding-source></award-group><funding-statement>This research was funded by The Science Technology and Innovation Committee of Shenzhen Municipality, grant number JCYJ20180507181627057; RGC General Research Fund of Hong Kong Special Administrative Region, grant number 11104020; and Strategic Funds from City University of Hong Kong to M. He.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-01349"><title>1. Introduction</title><p>The invention of vaccines and vaccination is one of the greatest public health achievements. Vaccines can mimic infection and elicit specific acquired immunity against disease infection [<xref rid="B1-pharmaceutics-15-01349" ref-type="bibr">1</xref>]. The World Health Organization (WHO) estimates that vaccination can prevent 3.5 to 5 million deaths each year [<xref rid="B2-pharmaceutics-15-01349" ref-type="bibr">2</xref>]. As a result, vaccination is one of the most powerful tools for protecting people from infectious diseases. Despite the success of the vaccine era, currently, around 15 million people worldwide die each year from various infectious diseases [<xref rid="B3-pharmaceutics-15-01349" ref-type="bibr">3</xref>]. The major bottleneck is the strict low-temperature conditions required for the storage and transportation of vaccines. Another barrier is the shortage of professional medical personnel in some areas [<xref rid="B4-pharmaceutics-15-01349" ref-type="bibr">4</xref>]. Portnoy et al. calculated that the cost of vaccination in 94 low- and middle-income countries over a ten-year period from 2011 to 2020 was about USD 62 billion, of which the delivery cost and supply chain cost were USD 34 billion and USD 4 billion, accounting for 54% and 6% of the total cost, respectively [<xref rid="B5-pharmaceutics-15-01349" ref-type="bibr">5</xref>]. The high cost of vaccines has seriously hindered vaccine coverage in these countries. Their lack of professional medical staff further restricts the large-scale vaccination. Currently, syringe injection into the subcutaneous tissue or muscle is the most common way for vaccination. In fact, due to pain, needle shaft damage, needle reuse, and poor patient compliance, a large proportion of people reject vaccination, which limits vaccine coverage [<xref rid="B6-pharmaceutics-15-01349" ref-type="bibr">6</xref>]. Therefore, a novel development of vaccines and mass vaccination remain top priorities for WHO.</p><p>To overcome the problems mentioned above, microneedle (MN) delivery of vaccines has come into the spotlight. MNs consist of a series of needles with a length controlled within 1 mm and a bottom layer, which can easily pierce the stratum corneum by thumb pressing or by an applicator to deliver the vaccine into the skin (<xref rid="pharmaceutics-15-01349-f001" ref-type="fig">Figure 1</xref>). The needle tips of MNs do not penetrate into the subcutaneous tissue and do not touch blood vessels and nerves, which overcomes the problems of pain and wound bleeding caused by traditional syringe injection [<xref rid="B7-pharmaceutics-15-01349" ref-type="bibr">7</xref>]. Meanwhile, the skin layers beneath the stratum corneum are supported by a tight junction of immune-network-supporting response APCs, and the number of APCs in the epidermis and dermis is much greater than that in muscles, including Langerhans cells (LCs) and dendrite cells (DCs). LCs represent 1&#8211;5% of all epidermal cells, which are located mainly at the suprabasal layer of the epidermis [<xref rid="B8-pharmaceutics-15-01349" ref-type="bibr">8</xref>]. Meanwhile, DCs constitute a major part of the dense APC network in the dermal layer. Muscle contains only a small number of APCs, and humoral immunity mainly occurs with the intramuscular vaccine [<xref rid="B9-pharmaceutics-15-01349" ref-type="bibr">9</xref>]. The time difference between humoral immunity and cellular immune response provides opportunities for virus transmission and infection [<xref rid="B10-pharmaceutics-15-01349" ref-type="bibr">10</xref>]. Skin vaccination has proven to induce similar antibody titers using doses lower than those used for the intramuscular (i.m.) route (that is, a dose-sparing effect) [<xref rid="B11-pharmaceutics-15-01349" ref-type="bibr">11</xref>]. Liu et al. proved that antigen <underline>ovalbumin</underline>&#160;(OVA)-loaded NPs delivered via a hollow microneedle array (hMN) elicited a significantly higher <underline>IgG2a antibody</underline>&#160;response&#160;in comparison to antigen-loaded NPs delivered by <underline>intramuscular injection</underline> [<xref rid="B12-pharmaceutics-15-01349" ref-type="bibr">12</xref>]. Although a vaccine using the Mantoux technique also uses an intradermal route, it has a higher frequency of pain and itching than the intramuscular group [<xref rid="B13-pharmaceutics-15-01349" ref-type="bibr">13</xref>]. The Bacillus Calmette-Gu&#233;rin (BCG) vaccine is the only Essential Programme on Immunization (EPI) vaccine that is given intradermally. Hiraishi et al. reported the design and engineering of a BCG-coated microneedle vaccine patch for a simple and improved intradermal delivery of the vaccine. The response was comparable to the traditional intradermal BCG vaccination, which could facilitate increased coverage, especially in developing countries that lack an adequate healthcare infrastructure [<xref rid="B14-pharmaceutics-15-01349" ref-type="bibr">14</xref>]. In addition, with the exception of the hMN, most MN-based vaccines are in an anhydrous form and reduce reliance on cold chain by limiting the vibration of molecules to heat, allowing stable storage of vaccines [<xref rid="B15-pharmaceutics-15-01349" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-15-01349" ref-type="bibr">16</xref>].</p><p>MN-based vaccines can also be conducted by self-injection, which greatly improves the vaccination rate in special populations. <xref rid="pharmaceutics-15-01349-t001" ref-type="table">Table 1</xref> compares the differences between MN-based vaccines and traditional injection vaccines.</p><p>Several important milestones in MN development are illustrated (<xref rid="pharmaceutics-15-01349-f002" ref-type="fig">Figure 2</xref>). The first study of sMN immunization was conducted in 2002. Mikszta et al. used a novel micro-enhanced array (MEA) to break the skin barrier and deliver the vaccine locally in vivo for the first time [<xref rid="B25-pharmaceutics-15-01349" ref-type="bibr">25</xref>]. MEA-based topical vaccines are more inducible than needle injections and require fewer vaccinations. This method effectively allows the vaccines to penetrate directly into the dermis, reducing skin irritation and eliminating pain and discomfort. In 2010, the first dMN were successfully used for influenza vaccination in the mice skin, which was well tolerated and generated a strong antibody response [<xref rid="B26-pharmaceutics-15-01349" ref-type="bibr">26</xref>]. Then, in 2015, an dMN-based vaccine was first tested in non-human primates [<xref rid="B27-pharmaceutics-15-01349" ref-type="bibr">27</xref>]. With the deepening research, the application of MN vaccines has become more and more extensive and includes the influenza vaccine, rabies vaccine [<xref rid="B28-pharmaceutics-15-01349" ref-type="bibr">28</xref>], HPV vaccine [<xref rid="B29-pharmaceutics-15-01349" ref-type="bibr">29</xref>] and so on. Now, researchers are applying MNs to the delivery of the COVID-19 vaccine [<xref rid="B30-pharmaceutics-15-01349" ref-type="bibr">30</xref>].</p><p>The coronavirus disease 2019 (COVID-19) pandemic has so far resulted in 625 million confirmed infections and more than 6.5 million deaths worldwide, which has overwhelmed health and economic systems [<xref rid="B31-pharmaceutics-15-01349" ref-type="bibr">31</xref>]. While candidate vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are rapidly being developed, achieving herd immunity remains a major obstacle for the immunization campaigns [<xref rid="B32-pharmaceutics-15-01349" ref-type="bibr">32</xref>]. At present, problems such as incomplete vaccine manufacturing capacity, high cost and strong dependence on cold chain supply have seriously hindered the popularization of vaccines [<xref rid="B33-pharmaceutics-15-01349" ref-type="bibr">33</xref>]. MN delivery of COVID-19 vaccines has the potential to address these issues, and it is likely to be an alternative to traditional injection vaccines, especially for special populations, which may greatly improve vaccine coverage.</p><p>This review systematically summarizes the development process of MNs, which overcome the limitations of traditional vaccination and provide a new way for vaccine delivery. We detail the possibility and utility of MNs for administering different types of vaccines, and we reveal their great potential to address the challenges of mass vaccination against COVID-19, especially in special populations.</p></sec><sec id="sec2-pharmaceutics-15-01349"><title>2. Development and Selection of MNs</title><p>MNs are a new type of physical penetration-enhancing technology that consist of multiple micron-level fine needle tips connected to the base in an array, or they may entail just one or several micro-needles connected to standard syringes, vials and carpules [<xref rid="B34-pharmaceutics-15-01349" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-15-01349" ref-type="bibr">35</xref>]. The needle body is generally 10&#8211;2000 &#956;m in height and 10&#8211;500 &#956;m in width. The advent of MN vaccination aims to make up for the inadequacies of traditional syringe injections. MNs penetrate the stratum corneum of the skin in a minimally invasive way to form reversible microtubule channels, allowing substances to reach the epidermis or dermis and spread through blood vessels, finally achieving systemic transmission [<xref rid="B36-pharmaceutics-15-01349" ref-type="bibr">36</xref>]. MNs are used in the administration of drugs and vaccines, in the cosmetic field, and in the treatment and diagnosis of diseases.</p><p>In 1958, Wagner first proposed the concept of MN intradermal injection and applied it for patent protection [<xref rid="B37-pharmaceutics-15-01349" ref-type="bibr">37</xref>]. In 1976, Gerstel and Place further proposed another patent for using MNs for transdermal drug delivery. They conceived a device that includes a drug-containing reservoir and multiple piercing protrusions extending from the surface of the reservoir that can pierce the stratum corneum of the skin to enhance transdermal drug delivery [<xref rid="B38-pharmaceutics-15-01349" ref-type="bibr">38</xref>]. However, the MN device had not received any practical application. Until 1995, an application breakthrough was achieved to prepare MN arrays on silicon wafers for the first time. Hashmi et al. used a microinjection to introduce foreign genes to Heterorhabditis bacteriophora HP88 [<xref rid="B39-pharmaceutics-15-01349" ref-type="bibr">39</xref>]. In 1998, Henry and others applied MNs to transdermal drug delivery and eventually achieved industrialization [<xref rid="B40-pharmaceutics-15-01349" ref-type="bibr">40</xref>]. Then, in 2002 [<xref rid="B25-pharmaceutics-15-01349" ref-type="bibr">25</xref>], Mikszta et al. opened a new chapter in the MN delivery of vaccines. The first human study with vaccine MNs appeared in 2009 [<xref rid="B41-pharmaceutics-15-01349" ref-type="bibr">41</xref>], and the first dMN-based vaccine was obtained in the following year [<xref rid="B42-pharmaceutics-15-01349" ref-type="bibr">42</xref>]. In 2014 and in the clinical trial of the MN vaccine in following year, Ma et al. delivered an HIV vaccine into the oral cavity using cMN to induce systemic and mucosal immune responses. Lastly, the FDA published a Regulatory Consideration for micro-needling devices in 2017 (<xref rid="pharmaceutics-15-01349-f002" ref-type="fig">Figure 2</xref>).</p><sec id="sec2dot1-pharmaceutics-15-01349"><title>2.1. Classification of MNs</title><p>MNs generally fall into five different depending on their delivery strategies: solid, coated, hollow, dissolving, and hydrogel-forming (<xref rid="pharmaceutics-15-01349-f003" ref-type="fig">Figure 3</xref>).</p><p>Solid MNs were the first generation and were made of metal materials and non-degradable polymers such as silicon and titanium dioxide. They are generally described as &#8220;poke and patch&#8221; due to their inability to carry the drug [<xref rid="B43-pharmaceutics-15-01349" ref-type="bibr">43</xref>]. They can pierce the skin, leaving a microchannel that allows drugs or vaccines to reach the dermis. Coated MNs were proposed to overcome the complexity of the two-step process in solid MNs [<xref rid="B44-pharmaceutics-15-01349" ref-type="bibr">44</xref>]. They load the active substances through the coating on the surface of the needle body, then release the deliverables into the capillaries through the intercellular fluid, and finally induce systemic treatment. They are described as &#8220;Coat and poke&#8221;, and the substances delivered are mainly water-soluble, which can be reused [<xref rid="B45-pharmaceutics-15-01349" ref-type="bibr">45</xref>]. An example is the successful preparation of smallpox vaccine-coated MNs by Chou et al., which turned out to be an alternative delivery system for traditional smallpox vaccination and storage [<xref rid="B46-pharmaceutics-15-01349" ref-type="bibr">46</xref>]. The hollow MNs can be understood as a microsyringe due to the cavity in the middle of the needles. When they pierce the skin, the vaccines preloaded in the cavity are driven by the concentration gradient to achieve delivery. They are usually made of hard materials such as silicon, metals and polymers [<xref rid="B47-pharmaceutics-15-01349" ref-type="bibr">47</xref>].</p><p>All three types of MNs mentioned above are at risk of breakage and generate sharps waste, which prompted the development of dissolving MNs [<xref rid="B48-pharmaceutics-15-01349" ref-type="bibr">48</xref>]. They are made of water-soluble biocompatible/biodegradable polymers or sugars. Dissolving MNs are often described as &#8220;Poke and release&#8221;. After penetrating the skin, the needles gradually dissolve in the skin tissue, and the substances contained in the needles are gradually released and absorbed by the body. Because of their advantages in delivering various therapeutic agents and vaccines, dissolving MNs have become widely used throughout the MN industry. Hydrogel MNs are usually made of cross-linked hydrogels or super-swollen polymers [<xref rid="B49-pharmaceutics-15-01349" ref-type="bibr">49</xref>]. They are used to deliver drugs by swelling or to diagnose by absorbing certain substances from interstitial fluid in the skin without dissolving.</p></sec><sec id="sec2dot2-pharmaceutics-15-01349"><title>2.2. Materials for the Preparation of MNs</title><p>The main attribute of MNs is their ability to penetrate the skin without breaking or bending. At present, the materials used for MNs are divided into three categories: inorganic materials, metals, and polymers (<xref rid="pharmaceutics-15-01349-f003" ref-type="fig">Figure 3</xref>).</p><p>Inorganic materials used in MNs include mainly silicon, glass, and ceramics. Silicon is the first and most frequently used material, which can be customized in different shapes and sizes for a wide range of applications. Although it has high hardness and can be easily inserted into the skin, silicon is brittle and can cause adverse effects if left in the skin [<xref rid="B50-pharmaceutics-15-01349" ref-type="bibr">50</xref>]. Because of this, scientists have used glass as a material to make MNs. Glass is now widely used for alumina, zirconia and calcium sulfate hemihydrate [<xref rid="B51-pharmaceutics-15-01349" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-15-01349" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-15-01349" ref-type="bibr">53</xref>]. However, glass is brittle and fragile. Scientists have begun to investigate biocompatible ceramic materials. For example, Vallhov et al. evaluated biodegradable ceramic (calcium sulfate) MNs and found that they could release drugs without triggering an immune response [<xref rid="B54-pharmaceutics-15-01349" ref-type="bibr">54</xref>].</p><p>Metals have been used in medical devices for decades. Biomedical metallic materials have good biocompatibility; gold, silver, platinum, stainless steel, cobalt-based and titanium-based alloys, etc. have mechanical properties useful in dentistry. Nickel-chromium stainless steel, cobalt-chromium-molybdenum alloys, titanium and their alloys are used in orthopedics, which are suitable materials for MNs. Among these, stainless steel, titanium, and nickel are often used for metal MNs [<xref rid="B55-pharmaceutics-15-01349" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-15-01349" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-15-01349" ref-type="bibr">57</xref>]. However, due to high hardness, non-biodegradability and inorganic materials, metals can only be used for solid, coated, or hollow MNs. Scientists further developed high molecular polymers to make dissolving and hydrogel MNs.</p><p>Polymer is a very promising material for MNs. Various biocompatible and biodegradable polymers have also been used to prepare MNs, such as hydrophobic poly (methyl methacrylate) (PMMA), Polyvinyl alcohol (PVA), Polyvinylpyrrolidone (PVP), polycaprolactone (PCL) and hydrophilic hyaluronic acid (HA), Carboxymethyl Cellulose (CMC), Polyethylene glycol (PEG) et al. [<xref rid="B58-pharmaceutics-15-01349" ref-type="bibr">58</xref>]. Polymers are not as rigid as silicon and metals, and they are commonly used to make dissolving and hydrogel MNs [<xref rid="B59-pharmaceutics-15-01349" ref-type="bibr">59</xref>].</p></sec></sec><sec id="sec3-pharmaceutics-15-01349"><title>3. Development of MNs Delivery of Vaccines</title><p>The development of society and technology is driving the progress of vaccines. In addition to the basic requirements of vaccines, such as sterility, safety and efficacy, modern vaccines also need to have the characteristics of low cost, high heat stability, convenient injection, and long-term immunity. MNs delivery of vaccines may meet those needs.</p><sec id="sec3dot1-pharmaceutics-15-01349"><title>3.1. Classification of Vaccines</title><p>Vaccines approved for human use in the pharmaceutical industry today fall into four main subcategories: live-attenuated vaccines, inactivated vaccines, pathogen component vaccines (DNA, RNA, proteins, virus-like particles (VLPs), etc.), and toxoid vaccines. Among them, live attenuated and inactivated vaccines are whole-agent vaccines, and pathogen component vaccines are subunit vaccines (<xref rid="pharmaceutics-15-01349-f004" ref-type="fig">Figure 4</xref>).</p><p>Currently commercialized vaccines are designed and produced based on these four types, as shown in <xref rid="pharmaceutics-15-01349-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3dot2-pharmaceutics-15-01349"><title>3.2. MNs Deliver Different Types of Vaccines</title><p>Mikszta et al. [<xref rid="B25-pharmaceutics-15-01349" ref-type="bibr">25</xref>] first tried MN immunization with a novel MEA in 2002 and successfully broke the skin barrier to deliver the vaccine to the body. Research on the delivery of vaccines via MNs has been intensively pursued after that (<xref rid="pharmaceutics-15-01349-f005" ref-type="fig">Figure 5</xref>).</p><sec id="sec3dot2dot1-pharmaceutics-15-01349"><title>3.2.1. Live-Attenuated Vaccine</title><p>Live-attenuated vaccines are whole vaccines in the form of weakened &#8220;wild&#8221; viruses or bacteria. When introduced into the body, they can trigger an immune response as with normal bacteria or viruses without causing harm or disease. However, these weakened forms are very likely to mutate back to the former wild type and cause fatal damage to the organism. Oral poliovirus vaccines, for example, can revert to their original toxic form, which can enter the central nervous system and cause paralysis in patients [<xref rid="B60-pharmaceutics-15-01349" ref-type="bibr">60</xref>]. In addition, vaccines are highly unstable at temperatures above 8 &#176;C. Professional operations are also required to maintain the cold chain for vaccine storage and transport. The use of MNs can reduce the need for low temperatures while ensuring a more stable state of vaccines, and it is safer and more convenient to operate.</p><p>In a study using the attenuated Japanese encephalitis vaccine ChimeriVax in non-human primates, it was found that the same dose of vaccine administered via skin micro abrasion and penetration with MNs produced stronger immunity than from subcutaneous injection [<xref rid="B73-pharmaceutics-15-01349" ref-type="bibr">73</xref>]. In addition, Edens et al. used dissolving MNs to deliver a live-attenuated measles vaccine to rhesus monkeys and found that MN vaccination produced higher antibody titers than subcutaneous vaccination. In addition, compared with commercially available freeze-dried and liquid vaccines, which can be stored for 90 days and only 7 days, respectively, the MN measles vaccine can retain about 90% of its potency after being stored at 40 &#176;C for 4 months [<xref rid="B27-pharmaceutics-15-01349" ref-type="bibr">27</xref>]. Prausnitz et al. also summarized the benefits of using MNs for measles and rubella vaccination, including the simplification of supply and cold chain, the elimination of needlestick waste, and the reduction of vaccination system costs. Hiraishi et al. used a microneedle patch (MNP) to efficiently deliver a BCG vaccine into the epidermis and dermis of the skin and elicit a robust cell-mediated immune response in the lungs and spleen of guinea pigs. This approach not only simplifies logistics and eliminates the hazards posed by hypodermic needles, but also promises to increase BCG vaccination rates [<xref rid="B14-pharmaceutics-15-01349" ref-type="bibr">14</xref>].</p></sec><sec id="sec3dot2dot2-pharmaceutics-15-01349"><title>3.2.2. Inactive Vaccine</title><p>Inactivated vaccines are produced by inactivating intact viruses or bacteria by chemical methods (beta-propiolactone, formalin, etc.) or physical methods (ultraviolet rays, electron beam irradiation, etc.) [<xref rid="B74-pharmaceutics-15-01349" ref-type="bibr">74</xref>]. Although this kind of vaccine is not effective as the live-attenuated vaccine, it is safer. Inactivated vaccines can induce massive immune responses by multiple injections or co-injection with adjuvants. Hepatitis A, hepatitis B, and influenza vaccines are all inactivated vaccines [<xref rid="B61-pharmaceutics-15-01349" ref-type="bibr">61</xref>]. To date, there are many examples of the successful use of MNs to deliver inactivated vaccines.</p><p>Hirschberg et al. used dissolving MNs to inject a hepatitis B vaccine containing aluminum hydroxide and lipopolysaccharide (LPS) adjuvant, and its primary immunization effect was comparable to the secondary immunization effect of a conventional vaccine containing liquid alum adjuvant [<xref rid="B63-pharmaceutics-15-01349" ref-type="bibr">63</xref>]. Moreover, the conventional vaccine lost 40% of its antigenicity after one week at 50 &#176;C, whereas the MN vaccine did not significantly decrease after three weeks at 50 &#176;C. This example successfully demonstrates that MN may be the most promising alternative to needle injection for hepatitis B vaccines. Frewab et al. evaluated the acceptability of an inactivated influenza vaccine delivered by MNP compared with an inactivated influenza vaccine (IIV) delivered by hypodermic needle [<xref rid="B64-pharmaceutics-15-01349" ref-type="bibr">64</xref>]. They screened 112 normal people in Atlanta, Georgia, and they found that participants also preferred the MNP for influenza vaccination and follow-up immunizations. Rodgers et al. successfully inserted and dissolved MNs ranging in size from 254 to 381 microns into the skin of mice. The results demonstrated that the bacterial load in the lungs of mice that had been inoculated with Pseudomonas aeruginosa was significantly lower than that of uninoculated mice. This work suggests the potential of dissolving MNs for intradermal vaccination against heat-killed bacteria [<xref rid="B65-pharmaceutics-15-01349" ref-type="bibr">65</xref>].</p></sec><sec id="sec3dot2dot3-pharmaceutics-15-01349"><title>3.2.3. Pathogen Component Vaccine</title><p>Pathogen vaccines are subunit vaccines and contain antigenic parts of viruses and bacteria. It can trigger an immune response without harming the subject [<xref rid="B75-pharmaceutics-15-01349" ref-type="bibr">75</xref>]. Pathogen vaccines include DNA, RNA, protein, and VLPs, and they resemble inactivated vaccines but are less immunogenic than live viruses or bacteria. They are safer but require multiple doses to achieve the desired level of the immune response [<xref rid="B76-pharmaceutics-15-01349" ref-type="bibr">76</xref>].</p><sec><title>DNA Vaccine</title><p>DNA vaccines have been studied since the early 1990s. They are antigen-encoding plasmid vectors containing a gene of interest [<xref rid="B77-pharmaceutics-15-01349" ref-type="bibr">77</xref>]. When the plasmid is transfected into myocytes or inoculated into APCs in skin or muscle, it triggers the transcription of the gene and the production of an antigenic protein, eliciting antigen-specific immune responses in vivo [<xref rid="B78-pharmaceutics-15-01349" ref-type="bibr">78</xref>]. The advantages of DNA vaccines are that they are more heat-resistant than traditional forms of vaccines and can be easily mass-produced [<xref rid="B79-pharmaceutics-15-01349" ref-type="bibr">79</xref>]. DNA vaccines cannot be reverted to their original virulent form [<xref rid="B80-pharmaceutics-15-01349" ref-type="bibr">80</xref>].</p><p>Arya et al. evaluated the safety and immunogenicity of MNP vaccination with a rabies DNA vaccine [<xref rid="B81-pharmaceutics-15-01349" ref-type="bibr">81</xref>]. The vaccine in the MNP was stable at 4 &#176;C for at least three weeks, and the MNP was well tolerated in the skin, with complete resolution of skin reactions within seven days and no systemic side effects. The immunogenicity of the MNP outperformed the intramuscular injection of the same vaccine dose. Dissolving MNPs may provide an innovative approach for mass rabies vaccination [<xref rid="B28-pharmaceutics-15-01349" ref-type="bibr">28</xref>]. Cole et al. used MNs to enhance the immunogenicity of DNA vaccines [<xref rid="B82-pharmaceutics-15-01349" ref-type="bibr">82</xref>]. This approach not only improves DNA stability in solid matrices, but also increases DNA delivery ability compared to sMN. To achieve an effective transdermal vaccine and targeted delivery in developing countries, Hu et al. utilized the MN delivery of a DNA vaccine for the treatment of malignant melanoma. The results showed that the MN-delivered vaccine induced significant therapeutic anti-tumor immunity and inhibited cancer cells growth, which is a potential immunotherapy strategy for MM [<xref rid="B66-pharmaceutics-15-01349" ref-type="bibr">66</xref>]. Liao et al. synthesized DNA multiplex vaccines in a single step in an MNP. It can be stored at 45 &#176;C for at least 4 months, which has a significant impact on effective vaccination in developing countries [<xref rid="B83-pharmaceutics-15-01349" ref-type="bibr">83</xref>]. In addition, Qiu et al. developed a hepatitis B DNA vaccine system based on a soluble microneedle array that can induce an effective immune response [<xref rid="B67-pharmaceutics-15-01349" ref-type="bibr">67</xref>].</p></sec><sec><title>RNA Vaccine</title><p>RNA vaccines function by introducing an mRNA sequence that encodes a specific antigen [<xref rid="B84-pharmaceutics-15-01349" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-15-01349" ref-type="bibr">85</xref>]. The vaccine introduces molecules of antigen-encoding mRNA, and the designed mRNA serves as a blueprint for building a foreign protein that would normally be produced by a pathogen (e.g., a virus) or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells [<xref rid="B60-pharmaceutics-15-01349" ref-type="bibr">60</xref>]. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and facilitate their uptake into cells [<xref rid="B86-pharmaceutics-15-01349" ref-type="bibr">86</xref>].</p><p>Since Nair and Boczkwoski first successfully demonstrated mRNA-based cancer vaccination in 1996 [<xref rid="B87-pharmaceutics-15-01349" ref-type="bibr">87</xref>], scientists have been searching for the best mRNA delivery system in recent years. MNs have attracted considerable interest as a platform for delivering vaccines through the skin. Koh et al. reported a proof-of-concept study to produce, characterize, and therapeutically evaluate in vitro transcribed messenger RNA (mRNA) loaded into dissolving MNP (RNA patches) [<xref rid="B88-pharmaceutics-15-01349" ref-type="bibr">88</xref>]. They found that the physical and functional integrity of mRNA stored in the MNs were preserved for at least two weeks. The RNA MNP can mediate in vivo transgene expression of mRNA encoding luciferase for up to 72 h, and the transfection efficiency and kinetics are superior to subcutaneous injection. Golombek et al. evaluated the intradermal delivery of synthetic mRNA by injection with hollow MNs. In addition, an in vitro porcine skin model was established to analyze protein expression mediated by synthetic mRNA in the skin after intradermal administration [<xref rid="B89-pharmaceutics-15-01349" ref-type="bibr">89</xref>]. Using this model, the efficient delivery of synthetic mRNA was demonstrated to detect high levels of secreted humanized Gaussian hypolucidase (hGLuc) protein encoded by microinjection of synthetic mRNA. The use of MNs enables the patient-friendly, painless, and efficient delivery of synthetic mRNA into the dermis. This approach can be used for topical treatment of different skin diseases as well as for vaccination and immunotherapy. There are only two typical examples of RNA vaccine delivery using MNs so far. However, in the recent fight against COVID-19, the use of MNs to deliver RNA vaccines has been widely used, and we will present these in detail in <xref rid="sec4-pharmaceutics-15-01349" ref-type="sec">Section 4</xref>.</p></sec><sec><title>Protein Vaccine</title><p>Protein subunit vaccines contain specific isolated proteins from viral or bacterial pathogens to trigger protective immunity [<xref rid="B90-pharmaceutics-15-01349" ref-type="bibr">90</xref>]. Rather than injecting a whole pathogen to trigger an immune response, a protein vaccine is safer and more stable but more complex to manufacture. Generally, adjuvants are required to induce a strong immune response, and multiple injections are performed.</p><p>MNs can be used as a delivery tool to deliver protein vaccines efficiently. Yuan et al. delivered the F1 protein antigen of Yersinia pestis in MNs, which were successful in triggering an immune response against the plague in animals [<xref rid="B69-pharmaceutics-15-01349" ref-type="bibr">69</xref>]. Weldon et al. tested the hypothesis that a recombinant subunit influenza vaccine could be delivered to the skin via coated MNs [<xref rid="B70-pharmaceutics-15-01349" ref-type="bibr">70</xref>]. It was found that mice vaccinated with stable recombinant trimeric soluble hemagglutinin (sHA) by MN elicited a strong immune response. The mice were completely protected from lethal influenza virus infection, highlighting the benefits of this protein subunit vaccination. Wang et al. generated self-adjuvant protein nanoparticles that conserved influenza antigens and immunized mice by vaccinating the skin with dissolvable MNPs to enhance the strength and breadth of the immune response [<xref rid="B91-pharmaceutics-15-01349" ref-type="bibr">91</xref>]. They produced a bilayer protein nanoparticle, NA2-FliC/M2e, and demonstrated that this nanoparticle-based MNP skin vaccine could be developed as an independent or synergistic component of a universal influenza vaccination strategy.</p></sec><sec><title>VLP Vaccine</title><p>VLPs are nanoparticles composed of a subset of non-infectious viral components that are structurally similar to wild-type viruses but lack the viral genome. They are non-replicative and non-infectious, and can induce an immune response in the host. VLPs have good stability and are excellent vaccine carriers [<xref rid="B92-pharmaceutics-15-01349" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceutics-15-01349" ref-type="bibr">93</xref>].</p><p>Quan et al. used coated MNs to deliver influenza VLPs into mouse skin [<xref rid="B26-pharmaceutics-15-01349" ref-type="bibr">26</xref>]. It was found that the delivery of high doses of vaccine via MNs resulted in 100% protection against challenging influenza viruses. In contrast, unstable influenza VLPs and intramuscular vaccines weakened the immune system and provided only partial protection (&#8804;40%). A vaccine formulated with a coated MNP was shown to provide superior protection over intramuscular injection through dermal vaccination with potential dose maintenance. Ray et al. developed dissolving MNs that contained a candidate HPV vaccine consisting of Q&#946; VLPs [<xref rid="B23-pharmaceutics-15-01349" ref-type="bibr">23</xref>]. Compared with conventional subcutaneous injection, polymer MN delivery of Q&#946;-HPV produced similar levers of anti-HPV16 L2 IgG antibodies, with a lower (16.7%) intradermal dose required. In addition, the vaccine can remain stable in the MNs at room temperature for several months, which will effectively solve many problems related to the cold chain. This MNP vaccine not only saves vaccine doses, but is also easy to self-administer and minimally invasive, which enables the wide distribution of HPV vaccines and improves patient compliance. The Q&#946;-VLPs and their MN delivery technology are a plug-and-play system that can serve as a general platform with a wide range of applications. Guo et al. developed a novel tumor vaccine delivery strategy using a biodegradable microneedle patch (MN) that allows for the sustained release of tumor antigens and induces long-term antitumor responses [<xref rid="B94-pharmaceutics-15-01349" ref-type="bibr">94</xref>]. Kines et al. also demonstrated that mice immunized with HPV16 VLP-coated microneedles produced a robust neutralizing antibody response, and the MN delivery of freeze-dried HPV may provide a practical, heatable vaccine delivery method that can be evaluated clinically [<xref rid="B29-pharmaceutics-15-01349" ref-type="bibr">29</xref>].</p></sec></sec><sec id="sec3dot2dot4-pharmaceutics-15-01349"><title>3.2.4. Toxoid Vaccines</title><p>Toxoid vaccines use toxins (harmful products) produced by disease-causing bacteria that develop immunity against the disease-causing part of the bacteria rather than the bacteria themselves. A toxoid is an inactive toxin that has lost its ability to cause disease but retains its immunogenicity [<xref rid="B95-pharmaceutics-15-01349" ref-type="bibr">95</xref>]. Two vaccines contain toxoids as immunogens, namely the diphtheria and tetanus vaccines. Like some other vaccines, the toxoid vaccines require booster shots to provide lasting protection against disease. In recent years, numerous studies have been conducted on the use of microneedles to deliver toxoid vaccines [<xref rid="B96-pharmaceutics-15-01349" ref-type="bibr">96</xref>].</p><p>Groot et al. tested ceramic nanoporous microneedle arrays (MNAs), which are a novel MN drug delivery technology capable of delivering diphtheria toxoid (DT) and tetanus toxoid (TT) in vivo [<xref rid="B97-pharmaceutics-15-01349" ref-type="bibr">97</xref>]. The results showed that DT and TT can be successfully loaded into the tips of ceramic nanoporous MNs. By labeling the antigens with near-infrared fluorescence, they applied DT and TT-loaded nanoporous MNAs to mice skin in vivo and induced antigen-specific antibodies similar to those obtained with subcutaneous immunization at the same doses, opening the possibilities for future MN vaccination designs. Leone et al. achieved single and multiple injections of DT using dMNs and hMNs [<xref rid="B72-pharmaceutics-15-01349" ref-type="bibr">72</xref>]. The prepared dMN can penetrate the skin and be dissolved within 20 min to release the antigen all at once. Skin immunization with hMN was performed by repeated dose injections. The overall response to dissolved MN vaccination was higher than that of hMN, and the immune strength was also high in the absence of adjuvant. In conclusion, unadjuvanted dissolving MNs were proved to be promising delivery vehicles for vaccination. Pattarabhiran et al. investigated potent immune responses elicited by tetanus toxoid-antigen-dissolvable microneedles (TT-MN) in a mouse model [<xref rid="B71-pharmaceutics-15-01349" ref-type="bibr">71</xref>]. They prepared TT-MN by adding TT to the polymer mixture. The results showed that the MNs penetrated 130 microns deep into the mouse skin and dissolved completely within 1 h of insertion into the skin. The TT-MN group had higher antibody titers than the intramuscular injection group. This indicates that TT-MN can be developed as a minimally invasive system for percutaneous delivery of TT antigen.</p></sec></sec></sec><sec id="sec4-pharmaceutics-15-01349"><title>4. COVID-19 Vaccines and Their MNs Delivery</title><p>Vaccine candidates against SARS-CoV-2 were rapidly being developed one year after the COVID-19 outbreak, and more than 2 billion people worldwide have now been fully vaccinated.</p><sec id="sec4dot1-pharmaceutics-15-01349"><title>4.1. SARS-CoV-2</title><p>SARS-CoV-2 is a coronavirus strain of the respiratory disease that caused the COVID-19 pandemic [<xref rid="B98-pharmaceutics-15-01349" ref-type="bibr">98</xref>]. It is a positive single-stranded RNA virus with an envelope [<xref rid="B99-pharmaceutics-15-01349" ref-type="bibr">99</xref>] and belongs to the family Coronaviridae Betacoronavirus genus severe acute respiratory syndrome related coronavirus species [<xref rid="B100-pharmaceutics-15-01349" ref-type="bibr">100</xref>]. SARS-CoV-2 is the seventh-known coronavirus that can infect humans. Available evidence suggests that it is a zoonotic coronavirus, with close genetic similarity to bat coronaviruses [<xref rid="B101-pharmaceutics-15-01349" ref-type="bibr">101</xref>]. Research is ongoing as to whether it came directly from bats or indirectly from any intermediate host [<xref rid="B102-pharmaceutics-15-01349" ref-type="bibr">102</xref>]. The virus showed little genetic diversity, suggesting that a spillover event introducing SARS-CoV-2 into humans may have occurred in late 2019 [<xref rid="B103-pharmaceutics-15-01349" ref-type="bibr">103</xref>]. Epidemiological studies estimated that the primary reproduction number (R0) of SARS-CoV-2 was on average 2.4 to 3.4 between December 2019 and September 2020 [<xref rid="B104-pharmaceutics-15-01349" ref-type="bibr">104</xref>]. However, some subsequent variants became more contagious, such as Delta (B.1.617.2 and AY lineage) and Omicron (B.1.1.529, BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages).</p><p>The virus can invade the human body through the upper respiratory tract, and it uses the Angiotensin-converting enzyme 2 (ACE2) receptor to enter host cells. The main infected organs include the lungs, heart, kidneys and other major organs [<xref rid="B105-pharmaceutics-15-01349" ref-type="bibr">105</xref>]. Human patients infected with the virus have no unique clinical symptoms, most of which are low-grade fever, weakness, oral and nasal symptoms, and dry cough, and some are accompanied by gastrointestinal discomfort [<xref rid="B106-pharmaceutics-15-01349" ref-type="bibr">106</xref>] (<xref rid="pharmaceutics-15-01349-f006" ref-type="fig">Figure 6</xref>).</p></sec><sec id="sec4dot2-pharmaceutics-15-01349"><title>4.2. Types of COVID-19 Vaccines</title><p>In the aftermath of the outbreak of the pandemic, various scientific research units and vaccine companies have been working on developing various COVID-19 vaccines, all of which can teach the human immune system to safely recognize and block the virus. As of Oct 2022, there are more than 700 vaccines under development in preclinical or clinical trials, and more than 220 COVID-19 vaccine candidates are in development. Among them, at least 85 vaccine candidates are in human trials, and 40 vaccines have been approved by the FDA for production use (<xref rid="pharmaceutics-15-01349-f007" ref-type="fig">Figure 7</xref>).</p><p>There are two broad categories of COVID-19 vaccines, including whole viral vaccines and component viral vaccines similar to those described in <xref rid="sec3-pharmaceutics-15-01349" ref-type="sec">Section 3</xref>. Whole-virus vaccines include inactivated vaccines and live-attenuated vaccines; component vaccines include recombinant subunit vaccines, viral vector vaccines, and nucleic acid vaccines (<xref rid="pharmaceutics-15-01349-f008" ref-type="fig">Figure 8</xref>).</p></sec><sec id="sec4dot3-pharmaceutics-15-01349"><title>4.3. MN Delivery of COVID-19 Vaccine</title><p>In 2020, Kim successfully delivered the COVID-19 recombinant protein vaccine using dissolving MNs, which kicked off this field [<xref rid="B30-pharmaceutics-15-01349" ref-type="bibr">30</xref>]. As of October 2022, a total of 44 related papers have been published, as shown in <xref rid="pharmaceutics-15-01349-f009" ref-type="fig">Figure 9</xref>. <xref rid="pharmaceutics-15-01349-t003" ref-type="table">Table 3</xref> shows the development of different MN delivery of COVID-19 vaccine with their benefits and drawbacks.</p><sec id="sec4dot3dot1-pharmaceutics-15-01349"><title>4.3.1. Whole-Virus Vaccine</title><p>Whole-virus vaccines are made by using chemical or physical methods such as formaldehyde or heat to kill the viral pathogen completely or partially, followed by purification and the addition of adjuvants. Such systems are very mature and are a massive production. It is a priority development technology for vaccines in response to COVID-19 outbreaks. Many whole-virus vaccines are currently available, such as BBIBP-CorV developed by the Beijing Institute of Biological Products (BBPI) of China Pharmaceutical Group [<xref rid="B107-pharmaceutics-15-01349" ref-type="bibr">107</xref>]. CoronaVac (also known as the Sinovac COVID-19 Vaccine) was developed by Sinovac, a biopharmaceutical company in mainland China [<xref rid="B108-pharmaceutics-15-01349" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceutics-15-01349" ref-type="bibr">109</xref>]. The Indian COVID-19 vaccine Covaxin (BBV152) was created by Bharat Biotechnology and the Indian Council of Medical Research [<xref rid="B90-pharmaceutics-15-01349" ref-type="bibr">90</xref>]. The WHO included the above three vaccines on the &#8220;Emergency use list&#8221; in May, June, and November 2021, respectively.</p><p>Li et al. developed a smart mushroom-inspired printable and mildly detachable (MILD) MN platform for the efficient and convenient delivery of multiple-dose COVID-19 vaccines and decentralized vaccine information storage. The MILD system induced high levels of antibodies in vivo after loading with an inactivated SARS-CoV-2 virus vaccine, which is a promising vehicle that has the potential to help contain the COVID-19 pandemic [<xref rid="B16-pharmaceutics-15-01349" ref-type="bibr">16</xref>].</p></sec><sec id="sec4dot3dot2-pharmaceutics-15-01349"><title>4.3.2. Recombinant Subunit Vaccine</title><p>Recombinant subunit vaccines contain only selected parts of pathogens and are very safe and stable. The expression vector containing the target antigen gene is transfected into an engineered cell line, and large quantities of the expression-target protein is purified; finally, the recombinant subunit vaccine can be prepared after adding an adjuvant. The preparation technology of recombinant subunit vaccines is mature, and there are currently more than 50 protein subunit vaccines in development [<xref rid="B110-pharmaceutics-15-01349" ref-type="bibr">110</xref>]. In clinical trials, the overall protection rate of subunit vaccines is higher than that of inactivated vaccines, which are also suitable for immunocompromised individuals. However, their manufacturing is more complex and requires adjuvant co-injection.</p><p>The first vaccine to be successfully delivered using MNs was a recombinant protein vaccine [<xref rid="B30-pharmaceutics-15-01349" ref-type="bibr">30</xref>]. Afterwards, Kuwentrai et al. prepared MNs with low molecular weight hyaluronic acid (HA) as support material for the delivery of S-RBD protein vaccines. HA is a naturally occurring skin substance that can be rapidly dissolved in skin tissue fluid. The results showed that the MN-based minimally invasive intradermal vaccine effectively penetrated the skin of mice, eliciting significant B-cell antibody responses and inducing interferon-gamma (IFN-&#947;)-based T-cell responses, which may control the rapid COVID-19 outbreaks [<xref rid="B111-pharmaceutics-15-01349" ref-type="bibr">111</xref>]. McMillan et al. used a high-density microarray patch (HD-MAP) to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin, which indicated that the vaccine was thermostable on the patch and enhanced cellular and antibody immune responses. In an ACE2 transgenic mouse model, a single dose of HD-MAP-delivered spikes provided complete protection against a lethal viral challenge. HD-MAP-delivered vaccines are superior to traditional needle and syringe vaccinations and could be an important addition to the ongoing COVID-19 pandemic [<xref rid="B81-pharmaceutics-15-01349" ref-type="bibr">81</xref>].</p></sec><sec id="sec4dot3dot3-pharmaceutics-15-01349"><title>4.3.3. Viral Vector Vaccines</title><p>Viral vector vaccines are produced by constructing a viral vector containing the target antigen gene and then delivering the genetic material that encodes another infectious pathogen-targeting antigen to the recipient&#8217;s host cell. It provides the genetic material to express antigens in cells and can induce a powerful cytotoxic T cell response. Adenoviral vectors are the most used viral vectors for this vaccine.</p><p>This type of vaccine mainly includes AstraZeneca, Satellite V, Johnson &amp; Johnson, Convidecia, etc. Oxford&#8211;AstraZeneca (AZD1222) is an improved non-replicating chimpanzee adenovirus vector (ChAdOx1) vaccine developed by the University of Oxford in cooperation with AstraZeneca Pharmaceuticals [<xref rid="B112-pharmaceutics-15-01349" ref-type="bibr">112</xref>]. This vaccine was placed on the emergency use list by the WHO on 15 February 2021 [<xref rid="B113-pharmaceutics-15-01349" ref-type="bibr">113</xref>]. Satellite V (&#1057;&#1087;&#1091;&#1090;&#1085;&#1080;&#1082; V) is a vaccine developed and registered by the State Research Center of Epidemiology and Microbiology in Gamaleya, Russia. Johnson &amp; Johnson&#8217;s COVID-19 vaccine is a human adenovirus-based viral vector vaccine developed by Janssen Vaccines in Leiden, the Netherlands and Janssen Pharmaceutica. Ad5-nCoV (Convidecia) is a single-dose recombinant adenovirus type 5 vector vaccine developed by CanSino Biological Co., Ltd. and the Institute of Bioengineering of the Academy of Military Medical Sciences of the Chinese People&#8217;s Liberation Army Academy of Sciences [<xref rid="B114-pharmaceutics-15-01349" ref-type="bibr">114</xref>]. Ad5-nCoV is the only currently approved COVID-19 vaccine that can use a single-dose vaccination program and is approved in China [<xref rid="B115-pharmaceutics-15-01349" ref-type="bibr">115</xref>]. Flynn et al. identified a dissolvable MNP for skin immunization to deliver the malaria vaccine AdHu5-PfRH5. Studies have shown that MNs can deliver low-dose adenovirus vaccines that are highly immunogenic. Moreover, the MNs also can stabilize the adenovirus vaccine [<xref rid="B116-pharmaceutics-15-01349" ref-type="bibr">116</xref>].</p></sec><sec id="sec4dot3dot4-pharmaceutics-15-01349"><title>4.3.4. Nucleic Acid Vaccines</title><p>Nucleic acid vaccines introduce specific antigen-encoding DNA or mRNA sequences into the cells of an organism to induce an immune response, preventing and treating diseases. Compared with traditional vaccines, genetic vaccines have the advantages of convenient design, high speed, and low production cost. Currently, there are more than 30 types of COVID-19 mRNA vaccines in preclinical or clinical trials around the world.</p><p>The Pfizer&#8211;BioNTech vaccine (BNT162b2, trade names: Comirnaty, Fubitai) is an mRNA vaccine jointly developed by BioNTech in Germany and Pfizer in the United States. It is the first nucleic acid vaccine approved by the WHO for the prevention of COVID-19 [<xref rid="B68-pharmaceutics-15-01349" ref-type="bibr">68</xref>]. The Moderna vaccine (mRNA-1273, trade name: Spikevax) was jointly developed by the National Institute of Allergy and Infectious Diseases at the Biomedical Advanced Research and Development Authority and Moderna Corporation [<xref rid="B117-pharmaceutics-15-01349" ref-type="bibr">117</xref>]. On 18 June 2022, the U.S. Food and Drug Administration (FDA) issued an emergency authorization for the use of Moderna and Pfizer&#8211;BioNTech vaccines in infants and young children over 6 months of age [<xref rid="B118-pharmaceutics-15-01349" ref-type="bibr">118</xref>]. The above two vaccines have launched mass vaccinations around the world; both of them have proven to be highly effective.</p><p>Caudill et al. used three-dimensional (3D) printing technology to design and fabricate multi-faceted coated (ovalbumin and CpG) MNAs. Compared with subcutaneous injection, these MNs not only enhanced vaccine retention in the skin, but also increased immune cell activation in the lymph nodes, which induced robust humoral and T-cell immune responses. CLIP 3D-printed MNs coated with vaccine components provide a useful platform for non-invasive, self-applied vaccination [<xref rid="B119-pharmaceutics-15-01349" ref-type="bibr">119</xref>]. Yin et al. developed a detachable MNP for delivering polymer-encapsulated spike (or nucleocapsid) proteins that encode DNA vaccines and immune adjuvants. Through the intradermal delivery of a nanovaccine, stronger and longer-lasting adaptive immunity compared to traditional injection vaccines were achieved. Additionally, the detachable MNP can be stored at room temperature for at least 30 days without reducing the immune response [<xref rid="B120-pharmaceutics-15-01349" ref-type="bibr">120</xref>]. Xia et al. then used an ultra-low-cost (&lt;$1) handheld (&lt;50 g) electroporation MN electrode array (&#8220;ePatch&#8221;) system for the DNA vaccination of SARS-CoV-2. The system induced robust adaptive immune responses in mice from at least 10-fold lower doses than traditional intramuscular or intradermal DNA vaccines [<xref rid="B20-pharmaceutics-15-01349" ref-type="bibr">20</xref>]. In the subsequent study, Kapnick et al. discussed the fact that MNAs could reduce barriers to vaccine access in under-resourced settings and could facilitate the rapid deployment of vaccines [<xref rid="B121-pharmaceutics-15-01349" ref-type="bibr">121</xref>].</p><table-wrap position="anchor" id="pharmaceutics-15-01349-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01349-t003_Table 3</object-id><label>Table 3</label><caption><p>Temporal development of different microneedle delivery of COVID-19 vaccine with their benefits and drawbacks.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Time</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MNs Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drawbacks</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 March 2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Produced higher levels of neutralizing antibodies. <break/>2: Reduced vaccine doses required to substantially reduce costs. <break/>3: Polymer matrix helps stabilize vaccine for at least 1 month. <break/>4: Potential for self-management.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Uncertainty in neutralizing antibody test results: only four weeks (reliable test is after six weeks). <break/>2: Immunogenicity also needs to be evaluated in clinical trials.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmaceutics-15-01349" ref-type="bibr">30</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 October 2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: minimally invasive. <break/>2: Significant antibody responses can be maintained for up to 97 days. <break/>3: Will not cause any damage to the environment. <break/>4: Facilitates rapid vaccination.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: This platform is not suitable for delivering mRNA. <break/>2: The titers of specific antibodies produced by the MN method vary widely. <break/>3: Sterility is difficult to guarantee.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-pharmaceutics-15-01349" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 February 2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector <break/>vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Incorporation of vaccine into patch significantly improves its thermal stability. <break/>2: MN delivery of vaccines enables. low-dose priming of immune response. <break/>3: Allow storage and distribution without cold chain.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Clinical data are difficult to obtain and lack robust statistical analysis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-pharmaceutics-15-01349" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 August 2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleic acid vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Non-intrusive and self-applying. <break/>2: Dose savings achieved. <break/>3: Realized the combination of rapid 3D printing technology and MN vaccine formulation, providing a versatile platform to improve global immunization and healthcare.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Potential safety hazards caused by needle tip breakage. <break/>2: Coated vaccine doses are limited.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-pharmaceutics-15-01349" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 August 2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Enhanced thermal stability of the vaccine and ease of handling. <break/>2: Did not have any noticeable side effects during in vivo vaccination.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Stability needs further investigation because DNA vaccine itself is relatively stable. <break/>2: Nanovaccine needs more clinical research.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-pharmaceutics-15-01349" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 September 2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sMN </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Ultra-low-cost (&lt;$1), handheld (&lt;50 g), battery-free electroporation microneedle vaccination system. <break/>2: Can save at least 10 times the vaccine dose. <break/>3: Vaccination was well tolerated with mild, transient skin effects.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: The electric field generated between the electrodes may cause skin and nerve irritation. <break/>2: The immune response is only characterized by pseudoviruses, and more detailed immunological characterization is required.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-pharmaceutics-15-01349" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 October 2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">recombinant protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Ease of self-administration, reduced cold chain dependency, and improved thermal stability. <break/>2: Facilitates improved vaccine transportation and delivery to patients in low- and middle-income countries <break/>3: Protection with just a single dose of the vaccine.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Antibody and/or cellular immunity induced by the vaccination regime needs further validation and may not be sufficient to suppress viral replication.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-pharmaceutics-15-01349" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 January 2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA Vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Helping lower barriers to vaccine access in resource-poor settings <break/>2: For contributions to the development of biomaterials for vaccine applications.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: mRNA vaccines are prone to degradation <break/>2: Antibody titers of MN vaccines vary, and precise dosing is challenging.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-pharmaceutics-15-01349" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 April 2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inactivated virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Helping vaccinators accurately record vaccination data. <break/>2: Easily self-administered by individuals. <break/>3: Patch base can be easily removed from the skin surface.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: There are currently no large-scale trials of vaccine delivery in large animals or humans.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-pharmaceutics-15-01349" ref-type="bibr">16</xref>]</td></tr></tbody></table></table-wrap><p>The study by DeSimone and his team found that their MNP produced 50 times more antibody titers than conventional injections [<xref rid="B119-pharmaceutics-15-01349" ref-type="bibr">119</xref>]. Furthermore, researchers in Queensland have also shown that their patch can provide a higher immune response than traditional syringes. They mentioned that even after COVID-19 is over, having this MN technology means that the world will be better prepared for the next epidemic [<xref rid="B81-pharmaceutics-15-01349" ref-type="bibr">81</xref>].</p></sec></sec><sec id="sec4dot4-pharmaceutics-15-01349"><title>4.4. Advantages and Challenges of MN Delivery of COVID-19 Vaccine</title><p>The development of MN undoubtedly provides a convenient alternative vaccination method for addressing the COVID-19 pandemic, which is conducive to increasing the popularization rate of the vaccine, especially at this stage when COVID-19 vaccination has been vigorously strengthened. There are many advantages to using MNs to inoculate the COVID-19 vaccine. It could not only lower the inoculation dose of the vaccination, but it also induces higher antibody levels. Because it is less invasive, easy to operate by itself, and has enhanced thermal stability, it has the potential to expand vaccination rates in low- and middle-income countries and special populations (infants, the elderly, and pillow phobias, etc.), which are expected to achieve full vaccine coverage.</p><p>However, there are currently many challenges for the MN delivery of the COVID-19 vaccine. During the drying, curing, and loading process of the MNs, the loading of the vaccine is difficult to make uniform, and there is great instability. Therefore, the corresponding antibody titers are also unstable. For sMNs or hMNs, potential safety hazards may be caused by needle tip breakage. Whether in the process of manufacturing or in storage, sterility is difficult to guarantee. Most importantly, there is little clinical data to support the immune response after vaccination, and there is long way to go before practical application.</p></sec></sec><sec id="sec5-pharmaceutics-15-01349"><title>5. Challenges and Prospects of MNs Delivery of Vaccines</title><p>MN vaccination solves the cold chain storage problem of vaccines to a large extent, saves vaccine dosage, and increases the accessibility of vaccination. Research on MN vaccination has become more and more extensive in recent years, and it is expected to become a new trend for future vaccination. However, there are still many challenges for the clinical translation and large-scale production of MN vaccines.</p><sec id="sec5dot1-pharmaceutics-15-01349"><title>5.1. Vaccine Waste</title><p>Multiple reports have demonstrated that MN delivery of smaller amounts of vaccine can achieve similar immune responses to high-dose intramuscular injections [<xref rid="B28-pharmaceutics-15-01349" ref-type="bibr">28</xref>,<xref rid="B119-pharmaceutics-15-01349" ref-type="bibr">119</xref>]. However, there is always a certain amount of vaccine loss in the drying and molding process of MNs, especially for cMN and dMN, which need strict molding and drying conditions [<xref rid="B46-pharmaceutics-15-01349" ref-type="bibr">46</xref>,<xref rid="B122-pharmaceutics-15-01349" ref-type="bibr">122</xref>]. These problems may be solved by finding more suitable MN materials and vaccine formulations.</p><p>In addition, vaccines may also cause losses during delivery. For example, after the hollow microneedle is pierced into the skin, the pinhole may be pressed by the skin tissue, making it difficult for the subsequent liquid or solid vaccine to penetrate into the skin, and the vaccine may be lost when the pillow is pulled out. For such cases, measures such as prolonging the delivery time and reducing the solvent volume should be adopted.</p></sec><sec id="sec5dot2-pharmaceutics-15-01349"><title>5.2. Vaccine Safety</title><p>As mentioned earlier in the article, strict control conditions are required for the production and storage, regardless if it is a full-dose or a component vaccine. The use of MNs to deliver vaccines increases thermal stability to a certain extent, but the sterilization of MN vaccines is challenging [<xref rid="B111-pharmaceutics-15-01349" ref-type="bibr">111</xref>]. The sterilization of sMN is straightforward, and commonly used methods include dry heat sterilization, moist heat sterilization, gamma radiation, etc. [<xref rid="B123-pharmaceutics-15-01349" ref-type="bibr">123</xref>], but it is usually not suitable for delivering vaccines. Vaccines are fragile bioactive components that need to be introduced into the body, usually using cMN or dMN for delivery. During the sterilization process, not only do the stability and activity of the vaccine components need to be maintained, but the supportability of the MN material also must be ensured. There are great challenges in the selection of sterilization methods, and some chemical and physical methods are almost not applicable [<xref rid="B124-pharmaceutics-15-01349" ref-type="bibr">124</xref>]. McCrudden et al. sterilized dMN loaded with the model drug ellipsoid protein (OVA) in different ways, including gamma irradiation, moist heat, and dry heat sterilization. It was found that the OVA components were either destroyed or not detected at all [<xref rid="B124-pharmaceutics-15-01349" ref-type="bibr">124</xref>]. Current studies have found that phthalene and electron beam sterilization may be effective methods for MN sterilization, but they cannot achieve complete sterility [<xref rid="B125-pharmaceutics-15-01349" ref-type="bibr">125</xref>]. Sterilization requires extensive research before entering commercial production and approval, which is one of the most important challenges in MN-delivered vaccine systems.</p><p>The immunogenicity of the skin makes it a highly sensitive organ for MN vaccine delivery, but MNs could also cause side effects such as mild and temporary erythema to the skin during the insertion process [<xref rid="B126-pharmaceutics-15-01349" ref-type="bibr">126</xref>]. This is one of the safety issues that should be considered with all types of MN vaccines. Before clinical trials, this issue must be strictly tested and evaluated.</p></sec><sec id="sec5dot3-pharmaceutics-15-01349"><title>5.3. Vaccine Degradation</title><p>Dissolving MNs can generally be dried at a relatively mild temperature (25&#8211;40 &#176;C) in the molding process, which will limit their applications for some vaccines. For example, recombinant protein vaccines are easily degraded when placed at room temperature for a period [<xref rid="B70-pharmaceutics-15-01349" ref-type="bibr">70</xref>]. In addition, the temperature can reach 100 &#176;C when curing MNs, especially during the methods of photolithography and wire drawing, which are likely to degrade the corresponding vaccine [<xref rid="B127-pharmaceutics-15-01349" ref-type="bibr">127</xref>]. For some heat-sensitive antigens, the temperature is even more critical.</p></sec><sec id="sec5dot4-pharmaceutics-15-01349"><title>5.4. Vaccine Loading</title><p>Most microneedle vaccines have a relatively limited loading capacity, except for hMN, which can only achieve continuous infusion or &#8220;on-demand&#8221; administration. CMN can only deliver about 1 mg of vaccine, while sMN and hydMN deliver vaccines depending on their needle volume and storage capacity [<xref rid="B69-pharmaceutics-15-01349" ref-type="bibr">69</xref>,<xref rid="B128-pharmaceutics-15-01349" ref-type="bibr">128</xref>]. After the hMN are inserted into the skin, the central outlet may be blocked by compressed skin tissue. Despite the potential of MNs to overcome the barrier properties of the skin, their success largely depends on the passive diffusion of vaccines in the skin. Other types of MNs also rely on this to deliver vaccines. Vaccines in particular require a threshold dose to induce immunity, and when passive diffusion is relied upon, antibody responses become erratic [<xref rid="B129-pharmaceutics-15-01349" ref-type="bibr">129</xref>]. This is also one of the insurmountable obstacles for MN vaccines. It requires continuous improvement of technology and manufacturing, the repeated testing of vaccine loads, and the use of large amounts of data to evaluate the degree of absorption of vaccines and other methods to solve the problem.</p></sec><sec id="sec5dot5-pharmaceutics-15-01349"><title>5.5. Prospects</title><p>Despite the aforementioned limitations and challenges of scaling up production, the commercial use of MNs to deliver vaccines has existed for more than a decade. Continuing advances in MN technology have enabled the painless delivery of a variety of vaccines. The drivers and potential benefits of MNs in vaccination are clear, including dose savings, elimination of the cold chain, improved safety, and potential self-administration. MN vaccines could greatly overcome vaccination barriers, eliminate the problem of unfair access to vaccines, and bring good news for the vaccination of special groups.</p><sec id="sec5dot5dot1-pharmaceutics-15-01349"><title>5.5.1. Practical Application of MNs Vaccines</title><p>The evidence and support for MN vaccination systems have grown in recent years. In 2020, the Vaccine Innovation Priorities Strategy (VIPS) Alliance [Bill &amp; Melinda Gates Foundation (BMGF), Garvey, UNICEF, PATH, WHO] recommended MN as one of three priority innovation to help overcome barriers to vaccination, ensure equitable access, improve vaccine effectiveness, and contribute to global health security [<xref rid="B130-pharmaceutics-15-01349" ref-type="bibr">130</xref>]. MNs are expected to be suitable for the delivery of different types of vaccines. The U.S. government provided USD 430,000 to four groups for developing MNP through the Biomedical Advanced Research and Development Authority (BARDA) on 18 August 2020 [<xref rid="B131-pharmaceutics-15-01349" ref-type="bibr">131</xref>]. Vaxxas is actively developing MN vaccines and is actively facing challenges with some partners, including BMGF, Merck and BARDA [<xref rid="B132-pharmaceutics-15-01349" ref-type="bibr">132</xref>]. Vaxxas is advancing an easy-to-use device for the MN delivery of IPV vaccines, designed to deliver vaccines into the skin. They observed significant vaccine dose savings in preclinical models. They also demonstrated this benefit in a Phase 1 clinical study, where the MN delivered a dose of seasonal fluluenza vaccine that required only one-sixth the standard dose for intramuscular injections [<xref rid="B133-pharmaceutics-15-01349" ref-type="bibr">133</xref>].</p><p>In addition, an easy-to-use vaccine-delivery MNP from the University of Connecticut (UConn) delivers the S protein on the coat of SARS-CoV-2 into the skin as an antigen against COVID-19. The technology could have far-reaching implications for improving vaccine coverage. On 17 May 2022, Emergex Vaccines Holding Limited (Emergex) announced the successful coating of its novel CD8+ T cell adaptive COVID-19 vaccine onto Zosano Pharma&#8217;s MNP. Zosano Pharmaceuticals has designed and manufactured a proprietary MNP system that consists of approximately 2000 drug-coated titanium MNs, and they successfully applied the Emergex COVID-19 vaccine candidate to MNs [<xref rid="B134-pharmaceutics-15-01349" ref-type="bibr">134</xref>]. Emergex and Zosano have demonstrated that Emergex&#8217;s COVID-19 vaccine is stable on plaques over a broad temperature range for up to six months at 40 &#176;C/75% relative humidity. Minimizing cold chain logistics could reduce the cost and efficiency of vaccination programs around the world and improve global preparedness for future pandemics and disease outbreaks [<xref rid="B135-pharmaceutics-15-01349" ref-type="bibr">135</xref>].</p><p>Micron Biomedical has also begun testing a measles-rubella vaccine based on dMN in children. The researchers assessed the safety, tolerability, and immunogenicity of the measles and rubella vaccines using MN technology compared with standard subcutaneous injections. It is worth mentioning that Micron chose Gambia, a sub-Saharan African country, as the clinical trial site, and enrolled 120 infants aged 15 to 18 months and 120 infants aged 9 to 10 months. This reflects a belief that MN technology is particularly well-suited for the administration of vaccines in areas of the world with special needs, as well as for people with special needs [<xref rid="B136-pharmaceutics-15-01349" ref-type="bibr">136</xref>].</p></sec><sec id="sec5dot5dot2-pharmaceutics-15-01349"><title>5.5.2. An Alternative Solution of Mass Vaccination in Special Population</title><p>While the world is encouraging vaccinations, vaccine coverage is still relatively limited, especially for special populations, which are also the main morbidity and mortality groups. The importance of vaccine equity has been made painfully clear by the COVID-19 pandemic; unvaccinated people are 15 times more likely to die from the disease than fully vaccinated people [<xref rid="B137-pharmaceutics-15-01349" ref-type="bibr">137</xref>]. Vaccines have all but eliminated infections such as measles, tetanus and polio. However, lack of access to a vaccine means these diseases remain a very real threat in many countries. Mark Prausnitz, a biomolecular engineer at the Georgia Institute of Technology, describes the measles shot as &#8220;cheap&#8221;. However, 15% of children worldwide do not even receive the first dose. Tens of thousands of children under five die each year from this preventable disease, almost exclusively in low- and middle-income countries [<xref rid="B138-pharmaceutics-15-01349" ref-type="bibr">138</xref>].</p><p>Courtney Jarrahian, who works on vaccine delivery at PATH, a global health nonprofit, said &#8220;The pandemic has shown us something very important, that diseases can spread and worsen in unvaccinated populations. Only when everyone has equal access to life-saving vaccines, health and safety around the world could be ensured. The key to ensuring that everyone has equal access to vaccines is to ensure that children in remote areas, vulnerable groups, and elderly people with limited mobility and poor physical fitness also have access to life-saving vaccines&#8221; [<xref rid="B139-pharmaceutics-15-01349" ref-type="bibr">139</xref>].</p><p>The current FDA and European Commission (EC)-approved COVID-19 vaccines must be refrigerated or frozen, so some remote or low-income countries and regions have extremely limited vaccine resources, and fewer people there can be vaccinated. If the use of MNs could get rid of the restrictions of the cold chain and reduce the number of vaccine preparations, people in these areas will have more opportunities to achieve vaccination. Additionally, the vaccination must be administered intramuscularly by trained medical staff in a qualified medical institution; some elderly or disabled people with limited mobility cannot be vaccinated without the companionship of their family members, but they happen to be a group of people with a weakened immune system who are in desperate need of vaccination [<xref rid="B140-pharmaceutics-15-01349" ref-type="bibr">140</xref>]. The emergence of MN vaccines could be one of the most efficient and convenient ways for them to get vaccinated. Just like sticking on a Band-Aid, they can achieve immunization by applying a little force on their arms or legs. Moreover, both fears of needles and the pain of immunizations prevent many children and people who are extremely sensitive to pain from getting vaccinated. Although some areas, such as Hong Kong, have opened the vaccination of COVID-19 to babies aged 6 months to 4 years, and a lot of evidence has proved that the vaccine is safe enough for babies, many parents still refuse to vaccinate their babies, largely because of the needle pain inflicted on the baby and the inconvenience [<xref rid="B141-pharmaceutics-15-01349" ref-type="bibr">141</xref>]. In addition, immune cells are not dense in muscles, and multiple injections, needle stick injuries, and unsafe injection procedures can lead to the risk of serious health problems, adding to the idea of parents refusing to vaccinate their babies. The skin is rich in APCs, so scientists have been investigating the use of MNs to deliver vaccines safely and painlessly into the skin, which not only eliminates many health risks, but also promises to achieve all the effects of the desired immune response. The provision of MN vaccines is now one of the top priorities, and more research is needed to explore its benefits in detail, as mentioned in the WHO report [<xref rid="B142-pharmaceutics-15-01349" ref-type="bibr">142</xref>].</p></sec></sec></sec><sec sec-type="conclusions" id="sec6-pharmaceutics-15-01349"><title>6. Conclusions</title><p>Interest in MNs has grown since its first appearance in the late 1990s, and many research groups and companies have attempted to efficiently manufacture various types of MNs; thus, they have emerged as promising transdermal drug and vaccine delivery devices. Vaccines are an essential part of pandemic preparedness, but their coverage is severely limited. Comprehensive vaccine coverage is extremely critical, especially for groups in remote areas and vulnerable groups (infants, young children afraid of pain and elderly people with limited mobility). Because of the supply chain and delivery challenges, pain and panic from needle sticks, needle contamination, and a lack of trained medical professionals, the emergence of MN delivery of vaccines has brought good news. Although technology, production and supervision challenges for MN vaccines remain, researchers and companies are actively joining in on new technology exploitation to facilitate MN vaccine inoculation. They work to provide boosters and alternatives to pandemic and routine vaccination.</p><p>The MN vaccine is expected to greatly increase the global vaccination rate and help meet the demand for full vaccine coverage. Moreover, having MN vaccination technology could help the world be better prepared for the next pandemic.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Y.-X.F. wrote this manuscript and prepared the figures and tables. Y.-X.F., H.H. and Y.-Y.W. modified this manuscript and adjust the format. X.Y. and M.-L.H. designed and supervised this project. All authors contributed to the article and approved the submitted version. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict financial interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-01349"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilleman</surname><given-names>M.R.</given-names></name></person-group><article-title>Vaccines in Historic Evolution and Perspective: A Narrative of Vaccine Discoveries</article-title><source>Vaccine</source><year>1999</year><volume>18</volume><fpage>1436</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00434-X</pub-id><pub-id pub-id-type="pmid">10618541</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-01349"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Vaccines and Immunization</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B3-pharmaceutics-15-01349"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>SDGs</collab></person-group><article-title>World Health Statistics 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://repository.gheli.harvard.edu/repository/11008/" ext-link-type="uri">https://repository.gheli.harvard.edu/repository/11008/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B4-pharmaceutics-15-01349"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.D.J.</given-names></name><name name-style="western"><surname>Sanoj Rejinold</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yeu-Chun</surname><given-names>K.</given-names></name></person-group><article-title>Microneedles for vaccine delivery: Challenges and future perspectives</article-title><source>Ther. Deliv.</source><year>2017</year><volume>8</volume><fpage>447</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">28530151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/tde-2017-0032</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-01349"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portnoy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grewal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Norman</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Rajgopal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorham</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Haidari</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.Y.</given-names></name></person-group><article-title>Costs of vaccine programs across 94 low- and middle-income countries</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>(Suppl. S1)</issue><fpage>A99</fpage><lpage>A108</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.12.037</pub-id><pub-id pub-id-type="pmid">25919184</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-01349"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Love</surname><given-names>R.J.</given-names></name></person-group><article-title>Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations</article-title><source>J. Prim. Care Community Health</source><year>2021</year><volume>12</volume><fpage>21501327211007393</fpage><pub-id pub-id-type="doi">10.1177/21501327211007393</pub-id><pub-id pub-id-type="pmid">33813931</pub-id><pub-id pub-id-type="pmcid">PMC8020217</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-01349"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weniger</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Papania</surname><given-names>M.J.</given-names></name></person-group><article-title>Alternative vaccine delivery methods</article-title><source>Vaccines</source><year>2013</year><fpage>1200</fpage><lpage>1231</lpage></element-citation></ref><ref id="B8-pharmaceutics-15-01349"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Combadiere</surname><given-names>B.</given-names></name></person-group><article-title>Tailored immunity by skin antigen-presenting cells</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.4161/hv.34299</pub-id><pub-id pub-id-type="pmid">25483512</pub-id><pub-id pub-id-type="pmcid">PMC4514408</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-01349"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>S.</given-names></name><name name-style="western"><surname>Engert</surname><given-names>J.</given-names></name></person-group><article-title>Recent insights into cutaneous immunization: How to vaccinate via the skin</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4663</fpage><lpage>4674</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.012</pub-id><pub-id pub-id-type="pmid">26006087</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-01349"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waltz</surname><given-names>E.</given-names></name></person-group><article-title>How nasal-spray vaccines could change the pandemic</article-title><source>Nature</source><year>2022</year><volume>609</volume><fpage>240</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/d41586-022-02824-3</pub-id><pub-id pub-id-type="pmid">36068305</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-01349"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lor&#233;</surname><given-names>K.</given-names></name></person-group><article-title>Local innate immune responses in the vaccine adjuvant-injected muscle</article-title><source>Clin. Transl. Immunol.</source><year>2016</year><volume>5</volume><fpage>e74</fpage><pub-id pub-id-type="doi">10.1038/cti.2016.19</pub-id><pub-id pub-id-type="pmcid">PMC4855268</pub-id><pub-id pub-id-type="pmid">27195117</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-01349"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Panyam</surname><given-names>J.</given-names></name></person-group><article-title>Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response</article-title><source>J. Control. Release</source><year>2019</year><volume>294</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.12.026</pub-id><pub-id pub-id-type="pmid">30572036</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-01349"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Atmar</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keitel</surname><given-names>W.A.</given-names></name></person-group><article-title>Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>1069</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis402</pub-id><pub-id pub-id-type="pmid">22891287</pub-id><pub-id pub-id-type="pmcid">PMC3501693</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-01349"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiraishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nandakumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.-O.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Posey</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sable</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Bacillus Calmette-Gu&#233;rin vaccination using a microneedle patch</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>2626</fpage><lpage>2636</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.042</pub-id><pub-id pub-id-type="pmid">21277407</pub-id><pub-id pub-id-type="pmcid">PMC3127204</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-01349"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baindara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A.</given-names></name></person-group><article-title>Thermostable vaccines: An innovative concept in vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2022</year><volume>21</volume><fpage>811</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2053678</pub-id><pub-id pub-id-type="pmid">35285366</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-01349"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><fpage>7512</fpage><lpage>7524</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c10718</pub-id><pub-id pub-id-type="pmid">35451839</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-01349"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manzoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Flacco</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>De Vito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Villari</surname><given-names>P.</given-names></name></person-group><article-title>Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses</article-title><source>Hum. Vaccin. Immunother.</source><year>2012</year><volume>8</volume><fpage>851</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.4161/hv.19917</pub-id><pub-id pub-id-type="pmid">22777099</pub-id><pub-id pub-id-type="pmcid">PMC3495721</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-01349"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuckerman</surname><given-names>J.N.</given-names></name></person-group><article-title>Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines</article-title><source>J. Med. Virol.</source><year>2006</year><volume>78</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1002/jmv.20524</pub-id><pub-id pub-id-type="pmid">16372285</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-01349"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darrah</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Zeppa</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Maiello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hackney</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wadsworth</surname><given-names>M.H.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Hughes</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Pokkali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>P.A.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Grant</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Prevention of tuberculosis in macaques after intravenous BCG immunization</article-title><source>Nature</source><year>2020</year><volume>577</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1817-8</pub-id><pub-id pub-id-type="pmid">31894150</pub-id><pub-id pub-id-type="pmcid">PMC7015856</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-01349"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Byagathvalli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Bhamla</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2110817118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2110817118</pub-id><pub-id pub-id-type="pmid">34670842</pub-id><pub-id pub-id-type="pmcid">PMC8609327</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-01349"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Application of microneedle-based vaccines in biosecurity</article-title><source>J. Biosaf. Biosecur.</source><year>2022</year><volume>4</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jobb.2022.04.001</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-01349"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Maaden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Trietsch</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kraan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Varypataki</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Romeijn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zwier</surname><given-names>R.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hankemeier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: A study with polio vaccine in rats</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>1846</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1007/s11095-013-1288-9</pub-id><pub-id pub-id-type="pmid">24469907</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-01349"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J.K.</given-names></name></person-group><article-title>Dissolving Microneedle Delivery of a Prophylactic HPV Vaccine</article-title><source>Biomacromolecules</source><year>2022</year><volume>23</volume><fpage>903</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.1c01345</pub-id><pub-id pub-id-type="pmid">35139303</pub-id><pub-id pub-id-type="pmcid">PMC9831510</pub-id></element-citation></ref><ref id="B24-pharmaceutics-15-01349"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtenay</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Novel Hydrogel-Forming Microneedle Array for Intradermal Vaccination in Mice Using Ovalbumin as a Model Protein Antigen</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00895</pub-id><pub-id pub-id-type="pmid">30452868</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-01349"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikszta</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Alarcon</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Brittingham</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Pettis</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>N.G.</given-names></name></person-group><article-title>Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery</article-title><source>Nat. Med.</source><year>2002</year><volume>8</volume><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nm0402-415</pub-id><pub-id pub-id-type="pmid">11927950</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-01349"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Vunnava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>7760</fpage><lpage>7769</lpage><pub-id pub-id-type="doi">10.1128/JVI.01849-09</pub-id><pub-id pub-id-type="pmid">20484519</pub-id><pub-id pub-id-type="pmcid">PMC2897640</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-01349"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Goodson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rota</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>A microneedle patch containing measles vaccine is immunogenic in non-human primates</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4712</fpage><lpage>4718</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.02.074</pub-id><pub-id pub-id-type="pmid">25770786</pub-id><pub-id pub-id-type="pmcid">PMC4554796</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-01349"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arya</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dewitt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scott-Garrard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Rabies vaccination in dogs using a dissolving microneedle patch</article-title><source>J. Control. Release</source><year>2016</year><volume>239</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.08.012</pub-id><pub-id pub-id-type="pmid">27524283</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-01349"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kines</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Zarnitsyn</surname><given-names>V.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Nicewonger</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Gangopadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0120797</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0120797</pub-id><pub-id pub-id-type="pmid">25785935</pub-id><pub-id pub-id-type="pmcid">PMC4364728</pub-id></element-citation></ref><ref id="B30-pharmaceutics-15-01349"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erdos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kenniston</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Balmert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Epperly</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><volume>55</volume><fpage>102743</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id><pub-id pub-id-type="pmcid">PMC7128973</pub-id></element-citation></ref><ref id="B31-pharmaceutics-15-01349"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO Coronavirus (COVID-19)</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B32-pharmaceutics-15-01349"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDermott</surname><given-names>A.</given-names></name></person-group><article-title>Core Concept: Herd immunity is an important-and often misunderstood-public health phenomenon</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2107692118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2107692118</pub-id><pub-id pub-id-type="pmid">34011611</pub-id><pub-id pub-id-type="pmcid">PMC8166024</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-01349"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeurissen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mossialos</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19 vaccine challenges: What have we learned so far and what remains to be done?</article-title><source>Health Policy</source><year>2021</year><volume>125</volume><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.healthpol.2021.03.013</pub-id><pub-id pub-id-type="pmid">33820678</pub-id><pub-id pub-id-type="pmcid">PMC7997052</pub-id></element-citation></ref><ref id="B34-pharmaceutics-15-01349"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vescovo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rettby</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramaniraka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liberman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cachemaille</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piveteau</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pantaleo</surname><given-names>G.</given-names></name></person-group><article-title>Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1782</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.09.069</pub-id><pub-id pub-id-type="pmid">28317660</pub-id></element-citation></ref><ref id="B35-pharmaceutics-15-01349"><label>35.</label><element-citation publication-type="webpage"><article-title>DebioJect Micro-Needles Intradermal Injections</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.debiotech.com/debioject/" ext-link-type="uri">https://www.debiotech.com/debioject/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B36-pharmaceutics-15-01349"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierre</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>F.C.</given-names></name></person-group><article-title>Microneedle-based drug delivery systems for transdermal route</article-title><source>Curr. Drug Targets</source><year>2014</year><volume>15</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.2174/13894501113146660232</pub-id><pub-id pub-id-type="pmid">24144208</pub-id></element-citation></ref><ref id="B37-pharmaceutics-15-01349"><label>37.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>A.R.</given-names></name></person-group><article-title>Article of Manufacture For Intracutaneous Injections</article-title><source>U.S. Patent</source><patent>2,893,392</patent><day>7</day><month>July</month><year>1959</year></element-citation></ref><ref id="B38-pharmaceutics-15-01349"><label>38.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Gerstel</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Place</surname><given-names>V.A.</given-names></name></person-group><article-title>Drug Delivery Device Background of the Invention</article-title><patent>US3964482A</patent><day>22</day><month>June</month><year>1976</year></element-citation></ref><ref id="B39-pharmaceutics-15-01349"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashmi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hashmi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaugler</surname><given-names>R.</given-names></name></person-group><article-title>Genetic Transformation of an Entomopathogenic Nematode by Microinjection</article-title><source>J. Invertebr. Pathol.</source><year>1994</year><volume>66</volume><fpage>293</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1006/jipa.1995.1103</pub-id><pub-id pub-id-type="pmid">8568284</pub-id></element-citation></ref><ref id="B40-pharmaceutics-15-01349"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henry</surname><given-names>S.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery</article-title><source>J. Pharm. Sci.</source><year>1998</year><volume>87</volume><fpage>922</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1021/js980042+</pub-id><pub-id pub-id-type="pmid">9687334</pub-id></element-citation></ref><ref id="B41-pharmaceutics-15-01349"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Mikszta</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cormier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name></person-group><article-title>Microneedle-based vaccines</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2009</year><volume>333</volume><fpage>369</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1007/978-3-540-92165-3_18</pub-id><pub-id pub-id-type="pmid">19768415</pub-id><pub-id pub-id-type="pmcid">PMC2904604</pub-id></element-citation></ref><ref id="B42-pharmaceutics-15-01349"><label>42.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Holly Korschun</surname><given-names>J.T.</given-names></name></person-group><article-title>Disappearing Needles: Vaccine-Delivery Patch with Dissolving Microneedles Eliminates &#8220;Sharps&#8221; Waste and Improves Protection</article-title><source>Fierce Biotech</source><day>20</day><month>July</month><year>2010</year></element-citation></ref><ref id="B43-pharmaceutics-15-01349"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hyung</surname><given-names>I.I.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>K.L.</given-names></name></person-group><source>A Solid Type Microneedle and Methods for Preparing It</source><publisher-name>World Intellectual Proprety Organisation</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2006</year></element-citation></ref><ref id="B44-pharmaceutics-15-01349"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Coated microneedles for transdermal delivery</article-title><source>J. Control. Release</source><year>2007</year><volume>117</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.10.017</pub-id><pub-id pub-id-type="pmid">17169459</pub-id><pub-id pub-id-type="pmcid">PMC1853346</pub-id></element-citation></ref><ref id="B45-pharmaceutics-15-01349"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.D.</given-names></name></person-group><article-title>Fabrication of coated polymer microneedles for transdermal drug delivery</article-title><source>J. Control. Release</source><year>2017</year><volume>265</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.03.383</pub-id><pub-id pub-id-type="pmid">28344014</pub-id></element-citation></ref><ref id="B46-pharmaceutics-15-01349"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.O.</given-names></name></person-group><article-title>Live Vaccinia Virus-Coated Microneedle Array Patches for Smallpox Vaccination and Stockpiling</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>209</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13020209</pub-id><pub-id pub-id-type="pmid">33546332</pub-id><pub-id pub-id-type="pmcid">PMC7913550</pub-id></element-citation></ref><ref id="B47-pharmaceutics-15-01349"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAllister</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Canatella</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>13755</fpage><lpage>13760</lpage><pub-id pub-id-type="doi">10.1073/pnas.2331316100</pub-id><pub-id pub-id-type="pmid">14623977</pub-id><pub-id pub-id-type="pmcid">PMC283494</pub-id></element-citation></ref><ref id="B48-pharmaceutics-15-01349"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahiji</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Dangol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name></person-group><article-title>A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>7914</fpage><pub-id pub-id-type="doi">10.1038/srep07914</pub-id><pub-id pub-id-type="pmid">25604728</pub-id><pub-id pub-id-type="pmcid">PMC4300505</pub-id></element-citation></ref><ref id="B49-pharmaceutics-15-01349"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Estrela</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leese</surname><given-names>H.S.</given-names></name></person-group><article-title>Hydrogel-Forming Microneedles: Current Advancements and Future Trends</article-title><source>Macromol. Biosci.</source><year>2021</year><volume>21</volume><fpage>e2000307</fpage><pub-id pub-id-type="doi">10.1002/mabi.202000307</pub-id><pub-id pub-id-type="pmid">33241641</pub-id></element-citation></ref><ref id="B50-pharmaceutics-15-01349"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradeep Narayanan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name></person-group><article-title>Solid silicon microneedles for drug delivery applications</article-title><source>Int. J. Adv. Manuf. Technol.</source><year>2016</year><volume>93</volume><fpage>407</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/s00170-016-9698-6</pub-id></element-citation></ref><ref id="B51-pharmaceutics-15-01349"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohebi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hajizadeh-Saffar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ghanian</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Zarkesh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Baharvand</surname><given-names>H.</given-names></name></person-group><article-title>Fabrication of microporous inorganic microneedles by centrifugal casting method for transdermal extraction and delivery</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>558</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.12.089</pub-id><pub-id pub-id-type="pmid">30654056</pub-id></element-citation></ref><ref id="B52-pharmaceutics-15-01349"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soltani-Arabshahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>D.L.</given-names></name></person-group><article-title>Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation</article-title><source>JAMA Dermatol.</source><year>2014</year><volume>150</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2013.6955</pub-id><pub-id pub-id-type="pmid">24258303</pub-id></element-citation></ref><ref id="B53-pharmaceutics-15-01349"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larra&#241;eta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lutton</surname><given-names>R.E.M.</given-names></name><name name-style="western"><surname>Woolfson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development</article-title><source>Mater. Sci. Eng. R Rep.</source><year>2016</year><volume>104</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.mser.2016.03.001</pub-id></element-citation></ref><ref id="B54-pharmaceutics-15-01349"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallhov</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Engqvist</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scheynius</surname><given-names>A.</given-names></name></person-group><article-title>Bioceramic microneedle arrays are able to deliver OVA to dendritic cells in human skin</article-title><source>J. Mater. Chem. B</source><year>2018</year><volume>6</volume><fpage>6808</fpage><lpage>6816</lpage><pub-id pub-id-type="doi">10.1039/C8TB01476K</pub-id><pub-id pub-id-type="pmid">32254697</pub-id></element-citation></ref><ref id="B55-pharmaceutics-15-01349"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mugo</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name></person-group><article-title>Modified stainless steel microneedle electrode for polyphenolics detection</article-title><source>Anal.Bioanal. Chem.</source><year>2020</year><volume>412</volume><fpage>7063</fpage><lpage>7072</lpage><pub-id pub-id-type="doi">10.1007/s00216-020-02836-w</pub-id><pub-id pub-id-type="pmid">32827071</pub-id></element-citation></ref><ref id="B56-pharmaceutics-15-01349"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Meinhart</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>N.C.</given-names></name></person-group><article-title>Bulk Micromachined Titanium Microneedles</article-title><source>J. Microelectromech. Syst.</source><year>2007</year><volume>16</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1109/JMEMS.2007.892909</pub-id></element-citation></ref><ref id="B57-pharmaceutics-15-01349"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dogra</surname><given-names>S.</given-names></name></person-group><article-title>A Cutaneous Reaction to Microneedling for Postacne Scarring Caused by Nickel Hypersensitivity</article-title><source>Aesthetic Surg. J.</source><year>2016</year><volume>36</volume><fpage>NP168</fpage><lpage>NP170</lpage><pub-id pub-id-type="doi">10.1093/asj/sjv229</pub-id><pub-id pub-id-type="pmid">26961992</pub-id></element-citation></ref><ref id="B58-pharmaceutics-15-01349"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Polymeric microneedles for controlled transdermal drug delivery</article-title><source>J. Control. Release</source><year>2019</year><volume>315</volume><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.10.022</pub-id><pub-id pub-id-type="pmid">31644938</pub-id></element-citation></ref><ref id="B59-pharmaceutics-15-01349"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbituyimana</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>Polymer-based microneedle composites for enhanced non-transdermal drug delivery</article-title><source>Appl. Mater. Today</source><year>2022</year><volume>29</volume><fpage>659</fpage><pub-id pub-id-type="doi">10.1016/j.apmt.2022.101659</pub-id></element-citation></ref><ref id="B60-pharmaceutics-15-01349"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>L.J.J.</given-names></name><name name-style="western"><surname>Daoussi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vervaet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Remon</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>De Beer</surname><given-names>T.R.M.</given-names></name></person-group><article-title>Freeze-drying of live virus vaccines: A review</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>5507</fpage><lpage>5519</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.085</pub-id><pub-id pub-id-type="pmid">26364685</pub-id></element-citation></ref><ref id="B61-pharmaceutics-15-01349"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elveborg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monteil</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Mirazimi</surname><given-names>A.</given-names></name></person-group><article-title>Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>271</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11020271</pub-id><pub-id pub-id-type="pmid">35215213</pub-id><pub-id pub-id-type="pmcid">PMC8879476</pub-id></element-citation></ref><ref id="B62-pharmaceutics-15-01349"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Goodson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rota</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>W.A.</given-names></name></person-group><article-title>A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination</article-title><source>Curr. Opin. Virol.</source><year>2020</year><volume>41</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2020.05.005</pub-id><pub-id pub-id-type="pmid">32622318</pub-id><pub-id pub-id-type="pmcid">PMC7497860</pub-id></element-citation></ref><ref id="B63-pharmaceutics-15-01349"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschberg</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>van de Wijdeven</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Kraan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amorij</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.F.</given-names></name></person-group><article-title>Bioneedles as alternative delivery system for hepatitis B vaccine</article-title><source>J. Control. Release</source><year>2010</year><volume>147</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.06.028</pub-id><pub-id pub-id-type="pmid">20620183</pub-id></element-citation></ref><ref id="B64-pharmaceutics-15-01349"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frew</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Paine</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schamel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>7175</fpage><lpage>7181</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.07.064</pub-id><pub-id pub-id-type="pmid">32792250</pub-id></element-citation></ref><ref id="B65-pharmaceutics-15-01349"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodgers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>Vincente-Perez</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Larraneta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kissenpfennig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: A proof of concept study</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>549</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.07.049</pub-id><pub-id pub-id-type="pmid">30048778</pub-id><pub-id pub-id-type="pmcid">PMC6127419</pub-id></element-citation></ref><ref id="B66-pharmaceutics-15-01349"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization</article-title><source>Polym. Chem.</source><year>2015</year><volume>6</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1039/C4PY01394H</pub-id></element-citation></ref><ref id="B67-pharmaceutics-15-01349"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>P.</given-names></name></person-group><article-title>DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>2391</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.992497</pub-id><pub-id pub-id-type="pmid">25625495</pub-id></element-citation></ref><ref id="B68-pharmaceutics-15-01349"><label>68.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Comirnaty, COVID 19 mRNA Vaccine</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.who.int/media/docs/default-source/immunization/covid-19/21040_chinese_vaccine-explainer_comirnaty-2.pdf?sfvrsn=271a9940_8" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/immunization/covid-19/21040_chinese_vaccine-explainer_comirnaty-2.pdf?sfvrsn=271a9940_8</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B69-pharmaceutics-15-01349"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.-F.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>M.-K.</given-names></name></person-group><article-title>Development of Yersinia pestis F1 antigen-loaded liposome vaccine against plague using microneedles as a delivery system</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>55</volume><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101443</pub-id></element-citation></ref><ref id="B70-pharmaceutics-15-01349"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weldon</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Zarnitsyn</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koutsonanos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>647</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1128/CVI.00435-10</pub-id><pub-id pub-id-type="pmid">21288996</pub-id><pub-id pub-id-type="pmcid">PMC3122571</pub-id></element-citation></ref><ref id="B71-pharmaceutics-15-01349"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pattarabhiran</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Saju</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Manimaran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Venuganti</surname><given-names>V.V.K.</given-names></name></person-group><article-title>Dissolvable Microneedle-Mediated Transcutaneous Delivery of Tetanus Toxoid Elicits Effective Immune Response</article-title><source>AAPS Pharm. Sci. Tech.</source><year>2019</year><volume>20</volume><fpage>257</fpage><pub-id pub-id-type="doi">10.1208/s12249-019-1471-3</pub-id><pub-id pub-id-type="pmid">31332640</pub-id></element-citation></ref><ref id="B72-pharmaceutics-15-01349"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romeijn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Le Devedec</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Vrieling</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Mahony</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name></person-group><article-title>Diphtheria toxoid dissolving microneedle vaccination: Adjuvant screening and effect of repeated-fractional dose administration</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>580</volume><fpage>119182</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119182</pub-id><pub-id pub-id-type="pmid">32119899</pub-id></element-citation></ref><ref id="B73-pharmaceutics-15-01349"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Alarcon</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Waterston</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Draper</surname><given-names>K.</given-names></name><name name-style="western"><surname>Early</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guirakhoo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Monath</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Mikszta</surname><given-names>J.A.</given-names></name></person-group><article-title>Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates</article-title><source>Hum. Vaccin.</source><year>2005</year><volume>1</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.4161/hv.1.3.1797</pub-id><pub-id pub-id-type="pmid">17012854</pub-id></element-citation></ref><ref id="B74-pharmaceutics-15-01349"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawar</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Murtadak</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Kale</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Parkhi</surname><given-names>S.S.</given-names></name></person-group><article-title>Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation</article-title><source>J. Virol. Methods</source><year>2015</year><volume>222</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2015.05.004</pub-id><pub-id pub-id-type="pmid">25997377</pub-id></element-citation></ref><ref id="B75-pharmaceutics-15-01349"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutsonanos</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>McMaster</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kalluri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kohlmeier</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4675</fpage><lpage>4682</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.086</pub-id><pub-id pub-id-type="pmid">25744228</pub-id><pub-id pub-id-type="pmcid">PMC5757502</pub-id></element-citation></ref><ref id="B76-pharmaceutics-15-01349"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boken</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sekulovich</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Percell</surname><given-names>S.A.E.I.</given-names></name><name name-style="western"><surname>Hirabayashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>R.L.</given-names></name></person-group><article-title>Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>180</volume><fpage>1700</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">10515836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/315060</pub-id></element-citation></ref><ref id="B77-pharmaceutics-15-01349"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutzler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>DNA vaccines: Ready for prime time?</article-title><source>Nat. Rev. Genet.</source><year>2008</year><volume>9</volume><fpage>776</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/nrg2432</pub-id><pub-id pub-id-type="pmid">18781156</pub-id><pub-id pub-id-type="pmcid">PMC4317294</pub-id></element-citation></ref><ref id="B78-pharmaceutics-15-01349"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maripat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>A.</given-names></name></person-group><article-title>Carson, and Helen Tighe. Gene Vaccination with Naked Plasmid DNA: Mechanism of CTL Priming</article-title><source>J. Exp. Med.</source><year>1996</year><volume>184</volume><fpage>1555</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">8879229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.184.4.1555</pub-id><pub-id pub-id-type="pmcid">PMC2192808</pub-id></element-citation></ref><ref id="B79-pharmaceutics-15-01349"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prather</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chartrain</surname><given-names>M.</given-names></name></person-group><article-title>Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production, and purification</article-title><source>Enzym. Microb. Technol.</source><year>2003</year><volume>33</volume><fpage>865</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/S0141-0229(03)00205-9</pub-id></element-citation></ref><ref id="B80-pharmaceutics-15-01349"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutzler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>Developing DNA vaccines that call to dendritic cells</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>114</volume><fpage>1241</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1172/JCI23467</pub-id><pub-id pub-id-type="pmid">15520855</pub-id><pub-id pub-id-type="pmcid">PMC524242</pub-id></element-citation></ref><ref id="B81-pharmaceutics-15-01349"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMillan</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Choo</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Idris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Supramaniam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amarilla</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Complete protection by a single-dose skin patch&#8211;delivered SARS-CoV-2 spike vaccine</article-title><source>Sci. Adv.</source><year>2021</year><volume>7</volume><fpage>eabj8065</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abj8065</pub-id><pub-id pub-id-type="pmid">34714668</pub-id><pub-id pub-id-type="pmcid">PMC8555896</pub-id></element-citation></ref><ref id="B82-pharmaceutics-15-01349"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>G.</given-names></name><name name-style="western"><surname>McCaffrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Vincente-Perez</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>H.O.</given-names></name></person-group><article-title>Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>50</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1248008</pub-id><pub-id pub-id-type="pmcid">PMC5287311</pub-id><pub-id pub-id-type="pmid">27846370</pub-id></element-citation></ref><ref id="B83-pharmaceutics-15-01349"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.W.</given-names></name></person-group><article-title>Self-Assembly DNA Polyplex Vaccine inside Dissolving Microneedles for High-Potency Intradermal Vaccination</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>2593</fpage><lpage>2605</lpage><pub-id pub-id-type="doi">10.7150/thno.19894</pub-id><pub-id pub-id-type="pmid">28819449</pub-id><pub-id pub-id-type="pmcid">PMC5558555</pub-id></element-citation></ref><ref id="B84-pharmaceutics-15-01349"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Non-viral COVID-19 vaccine delivery systems</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>169</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.12.008</pub-id><pub-id pub-id-type="pmid">33340620</pub-id><pub-id pub-id-type="pmcid">PMC7744276</pub-id></element-citation></ref><ref id="B85-pharmaceutics-15-01349"><label>85.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Blackburn</surname><given-names>L.</given-names></name></person-group><article-title>RNA Vaccines: An Introduction. Policy Briefing</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.grove-park.org/covid/800-VACCINE-INFO/mRNA-vaccines-an-introduction-briefing-note.pdf" ext-link-type="uri">https://www.grove-park.org/covid/800-VACCINE-INFO/mRNA-vaccines-an-introduction-briefing-note.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B86-pharmaceutics-15-01349"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rein Verbeke</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dewitte</surname><given-names>H.</given-names></name></person-group><article-title>Three decades of messenger RNA vaccine development</article-title><source>Nano Today</source><year>2019</year><volume>28</volume><fpage>10766</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2019.100766</pub-id></element-citation></ref><ref id="B87-pharmaceutics-15-01349"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boczkowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E.</given-names></name></person-group><article-title>Dendritic Cells Pulsed with RNA are Potent Antigen-presenting Cells In Vitro and In Vivo</article-title><source>J. Exp. Med.</source><year>1996</year><volume>184</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1084/jem.184.2.465</pub-id><pub-id pub-id-type="pmid">8760800</pub-id><pub-id pub-id-type="pmcid">PMC2192710</pub-id></element-citation></ref><ref id="B88-pharmaceutics-15-01349"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Phua</surname><given-names>K.K.L.</given-names></name></person-group><article-title>Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch)</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>11842</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-30290-3</pub-id><pub-id pub-id-type="pmid">30087399</pub-id><pub-id pub-id-type="pmcid">PMC6081392</pub-id></element-citation></ref><ref id="B89-pharmaceutics-15-01349"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golombek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steinle</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kochba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lunter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schlensak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wendel</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Avci-Adali</surname><given-names>M.</given-names></name></person-group><article-title>Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin</article-title><source>Mol. Ther. Nucleic Acids</source><year>2018</year><volume>11</volume><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2018.03.005</pub-id><pub-id pub-id-type="pmid">29858073</pub-id><pub-id pub-id-type="pmcid">PMC5992458</pub-id></element-citation></ref><ref id="B90-pharmaceutics-15-01349"><label>90.</label><element-citation publication-type="webpage"><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gavi.org/vaccineswork/what-are-protein-subunit-vaccines-and-how-could-they-be-used-against-covid-19" ext-link-type="uri">https://www.gavi.org/vaccineswork/what-are-protein-subunit-vaccines-and-how-could-they-be-used-against-covid-19</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B91-pharmaceutics-15-01349"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses</article-title><source>ACS Appl. Bio. Mater.</source><year>2021</year><volume>4</volume><fpage>4953</fpage><lpage>4961</lpage><pub-id pub-id-type="doi">10.1021/acsabm.1c00240</pub-id><pub-id pub-id-type="pmcid">PMC8232372</pub-id><pub-id pub-id-type="pmid">34179728</pub-id></element-citation></ref><ref id="B92-pharmaceutics-15-01349"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Donis</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles</article-title><source>Antivir. Res.</source><year>2010</year><volume>88</volume><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2010.09.001</pub-id><pub-id pub-id-type="pmid">20851715</pub-id><pub-id pub-id-type="pmcid">PMC2980851</pub-id></element-citation></ref><ref id="B93-pharmaceutics-15-01349"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Formulation of microneedles coated with influenza virus-like particle vaccine</article-title><source>AAPS Pharm. Sci. Tech.</source><year>2010</year><volume>11</volume><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1208/s12249-010-9471-3</pub-id><pub-id pub-id-type="pmid">20676947</pub-id><pub-id pub-id-type="pmcid">PMC2974157</pub-id></element-citation></ref><ref id="B94-pharmaceutics-15-01349"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name></person-group><article-title>Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine</article-title><source>Appl. Mater. Today</source><year>2021</year><volume>24</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1016/j.apmt.2021.101110</pub-id></element-citation></ref><ref id="B95-pharmaceutics-15-01349"><label>95.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Shabir</surname><given-names>O.</given-names></name></person-group><article-title>What Is a Toxoid Vaccine?</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.news-medical.net/health/What-is-a-Toxoid-Vaccine.aspx" ext-link-type="uri">https://www.news-medical.net/health/What-is-a-Toxoid-Vaccine.aspx</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B96-pharmaceutics-15-01349"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>A Dissolvable Microneedle Formulation of <italic toggle="yes">Bordetella pertussis</italic> Subunit Vaccine: Translational Development and Immunological Evaluation in Mice</article-title><source>ACS Appl. Bio. Mater.</source><year>2019</year><volume>2</volume><fpage>5053</fpage><lpage>5061</lpage><pub-id pub-id-type="doi">10.1021/acsabm.9b00730</pub-id><pub-id pub-id-type="pmid">35021503</pub-id></element-citation></ref><ref id="B97-pharmaceutics-15-01349"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Groot</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Platteel</surname><given-names>A.C.M.</given-names></name><name name-style="western"><surname>Kuijt</surname><given-names>N.</given-names></name><name name-style="western"><surname>van Kooten</surname><given-names>P.J.S.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Sijts</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Maaden</surname><given-names>K.</given-names></name></person-group><article-title>Nanoporous Microneedle Arrays Effectively Induce Antibody Responses against Diphtheria and Tetanus Toxoid</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1789</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01789</pub-id><pub-id pub-id-type="pmid">29375544</pub-id><pub-id pub-id-type="pmcid">PMC5770646</pub-id></element-citation></ref><ref id="B98-pharmaceutics-15-01349"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gulyaeva</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Lauber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leontovich</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Neuman</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome-related coronavirus: The species and its viruses&#8212;A statement of the Coronavirus Study Group</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>862</fpage><pub-id pub-id-type="doi">10.1101/2020.02.07.937862</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="B99-pharmaceutics-15-01349"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herskovitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Senan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oleynikov</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Blomberg</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Meigs</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections</article-title><source>J. Neuroimmune Pharmacol.</source><year>2020</year><volume>15</volume><fpage>359</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1007/s11481-020-09944-5</pub-id><pub-id pub-id-type="pmid">32696264</pub-id><pub-id pub-id-type="pmcid">PMC7373339</pub-id></element-citation></ref><ref id="B100-pharmaceutics-15-01349"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberfeld</surname><given-names>B.</given-names></name><name name-style="western"><surname>Achanta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilette</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Langat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Said</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Barczak</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>SnapShot: COVID-19</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>954</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.013</pub-id><pub-id pub-id-type="pmid">32413300</pub-id><pub-id pub-id-type="pmcid">PMC7190493</pub-id></element-citation></ref><ref id="B101-pharmaceutics-15-01349"><label>101.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.-R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-L.</given-names></name><etal/></person-group><article-title>Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin</article-title><source>bioRxiv</source><year>2020</year><comment><italic toggle="yes">in print</italic></comment><pub-id pub-id-type="doi">10.1101/2020.01.22.914952</pub-id></element-citation></ref><ref id="B102-pharmaceutics-15-01349"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#8217;Kovski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kratzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>V.</given-names></name></person-group><article-title>Coronavirus biology and replication: Implications for SARS-CoV-2</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id><pub-id pub-id-type="pmcid">PMC7592455</pub-id></element-citation></ref><ref id="B103-pharmaceutics-15-01349"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>Wuhan seafood market may not be source of novel virus spreading globally</article-title><source>Science</source><year>2020</year><volume>10</volume><fpage>1126</fpage><pub-id pub-id-type="doi">10.1126/science.abb0611</pub-id></element-citation></ref><ref id="B104-pharmaceutics-15-01349"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billah</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Miah</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.N.</given-names></name></person-group><article-title>Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0242128</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0242128</pub-id><pub-id pub-id-type="pmid">33175914</pub-id><pub-id pub-id-type="pmcid">PMC7657547</pub-id></element-citation></ref><ref id="B105-pharmaceutics-15-01349"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiergens</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Nitsche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271.e278</fpage><lpage>280.e278</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="B106-pharmaceutics-15-01349"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimohamadi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sepandi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taghdir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hosamirudsari</surname><given-names>H.</given-names></name></person-group><article-title>Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis</article-title><source>J. Prev. Med. Hyg.</source><year>2020</year><volume>61</volume><fpage>E304</fpage><lpage>E312</lpage><pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2020.61.3.1530</pub-id><pub-id pub-id-type="pmid">33150219</pub-id><pub-id pub-id-type="pmcid">PMC7595075</pub-id></element-citation></ref><ref id="B107-pharmaceutics-15-01349"><label>107.</label><element-citation publication-type="webpage"><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.xinhuanet.com/world/2021-05/07/c_1127419114.htm" ext-link-type="uri">http://www.xinhuanet.com/world/2021-05/07/c_1127419114.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B108-pharmaceutics-15-01349"><label>108.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO Recommendation of Sinovac COVID-19 vaccine (Vero Cell [Inactivated])&#8212;CoronaVac</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac" ext-link-type="uri">https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B109-pharmaceutics-15-01349"><label>109.</label><element-citation publication-type="webpage"><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://news.un.org/zh/story/2021/11/1093862" ext-link-type="uri">https://news.un.org/zh/story/2021/11/1093862</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B110-pharmaceutics-15-01349"><label>110.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>COVID-19 Vaccine Tracker</collab></person-group><article-title>Vaccines Candidates in Clinical Trials</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/#phase-3" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/#phase-3</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B111-pharmaceutics-15-01349"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuwentrai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice</article-title><source>Bioeng. Transl. Med.</source><year>2021</year><volume>6</volume><fpage>e10202</fpage><pub-id pub-id-type="doi">10.1002/btm2.10202</pub-id><pub-id pub-id-type="pmid">33349797</pub-id><pub-id pub-id-type="pmcid">PMC7744900</pub-id></element-citation></ref><ref id="B112-pharmaceutics-15-01349"><label>112.</label><element-citation publication-type="gov"><article-title>COVID-19 Vaccine AstraZeneca</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tga.gov.au/apm-summary/covid-19-vaccine-astrazeneca" ext-link-type="uri">https://www.tga.gov.au/apm-summary/covid-19-vaccine-astrazeneca</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B113-pharmaceutics-15-01349"><label>113.</label><element-citation publication-type="webpage"><article-title>Interim Recommendations for Use of the ChAdOx1-S [Recombinant] Vaccine against COVID-19 (AstraZeneca COVID-19 Vaccine AZD1222 Vaxzevria&#8482;, SII COVISHIELD&#8482;) 2021</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1/" ext-link-type="uri">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B114-pharmaceutics-15-01349"><label>114.</label><element-citation publication-type="webpage"><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bjnews.com.cn/detail/161434174815958.html" ext-link-type="uri">https://www.bjnews.com.cn/detail/161434174815958.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B115-pharmaceutics-15-01349"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halperin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>MacKinnon-Cameron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Ruiz-Palacios</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lourdes Guerrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mu&#241;oz Navarro</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(21)02753-7</pub-id><pub-id pub-id-type="pmid">34953526</pub-id><pub-id pub-id-type="pmcid">PMC8700283</pub-id></element-citation></ref><ref id="B116-pharmaceutics-15-01349"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dillane</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lanza</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silk</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.C.</given-names></name></person-group><article-title>Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>299</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9030299</pub-id><pub-id pub-id-type="pmid">33810085</pub-id><pub-id pub-id-type="pmcid">PMC8005075</pub-id></element-citation></ref><ref id="B117-pharmaceutics-15-01349"><label>117.</label><element-citation publication-type="webpage"><article-title>BBC</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://web.archive.org/web/20210428215106/https://www.bbc.com/zhongwen/trad/world-55375185" ext-link-type="uri">https://web.archive.org/web/20210428215106/https://www.bbc.com/zhongwen/trad/world-55375185</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B118-pharmaceutics-15-01349"><label>118.</label><element-citation publication-type="webpage"><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://web.archive.org/web/20220705190758/https://www.cna.com.tw/news/aopl/202206180003.aspx" ext-link-type="uri">https://web.archive.org/web/20220705190758/https://www.cna.com.tw/news/aopl/202206180003.aspx</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B119-pharmaceutics-15-01349"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caudill</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Iliadis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tessema</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mecham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2102595118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2102595118</pub-id><pub-id pub-id-type="pmid">34551974</pub-id><pub-id pub-id-type="pmcid">PMC8488660</pub-id></element-citation></ref><ref id="B120-pharmaceutics-15-01349"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>14347</fpage><lpage>14359</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c03252</pub-id><pub-id pub-id-type="pmid">34472328</pub-id></element-citation></ref><ref id="B121-pharmaceutics-15-01349"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapnick</surname><given-names>S.M.</given-names></name></person-group><article-title>The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response</article-title><source>DNA Cell Biol.</source><year>2022</year><volume>41</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1089/dna.2021.0538</pub-id><pub-id pub-id-type="pmid">34958232</pub-id><pub-id pub-id-type="pmcid">PMC8787697</pub-id></element-citation></ref><ref id="B122-pharmaceutics-15-01349"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M.H.</given-names></name></person-group><article-title>Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>3077</fpage><lpage>3086</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.12.041</pub-id><pub-id pub-id-type="pmid">23369214</pub-id></element-citation></ref><ref id="B123-pharmaceutics-15-01349"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatnagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gadeela</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Thathireddy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Venuganti</surname><given-names>V.V.K.</given-names></name></person-group><article-title>Microneedle-based drug delivery: Materials of construction</article-title><source>J. Chem. Sci.</source><year>2019</year><volume>131</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s12039-019-1666-x</pub-id></element-citation></ref><ref id="B124-pharmaceutics-15-01349"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCrudden</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Alkilani</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Courtenay</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>McCloskey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alshraiedeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lutton</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Woolfson</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Considerations in the sterile manufacture of polymeric microneedle arrays</article-title><source>Drug Deliv. Transl. Res.</source><year>2015</year><volume>5</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s13346-014-0211-1</pub-id><pub-id pub-id-type="pmid">25787335</pub-id></element-citation></ref><ref id="B125-pharmaceutics-15-01349"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shayan</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name></person-group><article-title>Physicochemical study of ascorbic acid 2-glucoside loaded hyaluronic acid dissolving microneedles irradiated by electron beam and gamma ray</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>180</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2017.10.044</pub-id><pub-id pub-id-type="pmid">29103509</pub-id></element-citation></ref><ref id="B126-pharmaceutics-15-01349"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.D.</given-names></name></person-group><article-title>Safety Assessment of Microneedle Technology for Transdermal Drug Delivery: A Review</article-title><source>Adv. Ther.</source><year>2020</year><volume>3</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1002/adtp.202000033</pub-id></element-citation></ref><ref id="B127-pharmaceutics-15-01349"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kathuria</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name></person-group><article-title>Rapid microneedle fabrication by heating and photolithography</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>575</volume><fpage>118992</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118992</pub-id><pub-id pub-id-type="pmid">31884060</pub-id></element-citation></ref><ref id="B128-pharmaceutics-15-01349"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zarnitsyn</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>7968</fpage><lpage>7973</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812652106</pub-id><pub-id pub-id-type="pmid">19416832</pub-id><pub-id pub-id-type="pmcid">PMC2683119</pub-id></element-citation></ref><ref id="B129-pharmaceutics-15-01349"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gumel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Iboi</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ngonghala</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Ngwa</surname><given-names>G.A.</given-names></name></person-group><article-title>Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S</article-title><source>Front. Public Health</source><year>2021</year><volume>9</volume><fpage>709369</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2021.709369</pub-id><pub-id pub-id-type="pmid">34368071</pub-id><pub-id pub-id-type="pmcid">PMC8343072</pub-id></element-citation></ref><ref id="B130-pharmaceutics-15-01349"><label>130.</label><element-citation publication-type="gov"><article-title>The Vaccine Innovation Prioritisation Strategy (VIPS)</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy" ext-link-type="uri">https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B131-pharmaceutics-15-01349"><label>131.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Medical Countermeasures.gov</collab></person-group><article-title>BARDA Establishes Four New Partnerships to Explore Innovative Vaccine Delivery Technologies</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.medicalcountermeasures.gov/newsroom/2020/barda-new-partnerships/" ext-link-type="uri">https://www.medicalcountermeasures.gov/newsroom/2020/barda-new-partnerships/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B132-pharmaceutics-15-01349"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>A.</given-names></name><name name-style="western"><surname>Junger</surname><given-names>M.</given-names></name></person-group><article-title>Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer&#8217;s perspective</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2050123</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2050123</pub-id><pub-id pub-id-type="pmcid">PMC9196745</pub-id><pub-id pub-id-type="pmid">35356872</pub-id></element-citation></ref><ref id="B133-pharmaceutics-15-01349"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Witham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Depelsenaire</surname><given-names>A.C.I.</given-names></name><name name-style="western"><surname>Veitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pryor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lickliter</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rockman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial</article-title><source>PLoS Med.</source><year>2020</year><volume>17</volume><elocation-id>e1003024</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003024</pub-id><pub-id pub-id-type="pmid">32181756</pub-id><pub-id pub-id-type="pmcid">PMC7077342</pub-id></element-citation></ref><ref id="B134-pharmaceutics-15-01349"><label>134.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Emergex COVID-19</collab></person-group><article-title>Vaccine Candidate Successfully Coated onto Zosano Micro-Needle Patch</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.contractpharma.com/contents/view_breaking-news/2022-05-17/emergex-covid-19-vaccine-candidate-successfully-coated-onto-zosano-micro-needle-patch" ext-link-type="uri">https://www.contractpharma.com/contents/view_breaking-news/2022-05-17/emergex-covid-19-vaccine-candidate-successfully-coated-onto-zosano-micro-needle-patch</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B135-pharmaceutics-15-01349"><label>135.</label><element-citation publication-type="webpage"><article-title>Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma&#8217;s Micro-Needle Patch</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.globenewswire.com/en/news-release/2022/05/17/2444730/0/en/Emergex-Vaccines-Announces-the-Successful-Coating-of-its-Novel-CD8-T-cell-Adaptive-COVID-19-Vaccine-onto-Zosano-Pharma-s-Micro-Needle-Patch.html" ext-link-type="uri">https://www.globenewswire.com/en/news-release/2022/05/17/2444730/0/en/Emergex-Vaccines-Announces-the-Successful-Coating-of-its-Novel-CD8-T-cell-Adaptive-COVID-19-Vaccine-onto-Zosano-Pharma-s-Micro-Needle-Patch.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B136-pharmaceutics-15-01349"><label>136.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>N.P.</given-names></name></person-group><article-title>In a first, Micron starts testing microneedle vaccine in kids</article-title><source>Firece Pharma.</source><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fiercepharma.com/drug-delivery/a-first-micron-starts-testing-microneedle-vaccine-kids" ext-link-type="uri">https://www.fiercepharma.com/drug-delivery/a-first-micron-starts-testing-microneedle-vaccine-kids</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B137-pharmaceutics-15-01349"><label>137.</label><element-citation publication-type="gov"><article-title>COVID Data Tracker</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home" ext-link-type="uri">https://covid.cdc.gov/covid-data-tracker/#datatracker-home</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B138-pharmaceutics-15-01349"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarmiento Su&#225;rez</surname><given-names>R.</given-names></name><collab>Local Burden of Disease Vaccine Coverage Collaborators</collab></person-group><article-title>Mapping routine measles vaccination in low- and middle-income countries</article-title><source>Nature</source><year>2021</year><volume>589</volume><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03043-4</pub-id><pub-id pub-id-type="pmid">33328634</pub-id><pub-id pub-id-type="pmcid">PMC7739806</pub-id></element-citation></ref><ref id="B139-pharmaceutics-15-01349"><label>139.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Thomasy</surname><given-names>H.</given-names></name></person-group><article-title>Tiny Needles Make a Big Impact for Vaccine Delivery</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.drugdiscoverynews.com/tiny-needles-make-a-big-impact-for-vaccine-delivery-15615" ext-link-type="uri">https://www.drugdiscoverynews.com/tiny-needles-make-a-big-impact-for-vaccine-delivery-15615</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B140-pharmaceutics-15-01349"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andryukov</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Besednova</surname><given-names>N.N.</given-names></name></person-group><article-title>Older adults: Panoramic view on the COVID-19 vaccination</article-title><source>AIMS Public Health</source><year>2021</year><volume>8</volume><fpage>388</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.3934/publichealth.2021030</pub-id><pub-id pub-id-type="pmid">34395690</pub-id><pub-id pub-id-type="pmcid">PMC8334630</pub-id></element-citation></ref><ref id="B141-pharmaceutics-15-01349"><label>141.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Healthcare-Pharmaceuticals</collab></person-group><article-title>Hong Kong Approves Baby Version of BioNTech Vaccine for Toddlers</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/business/healthcare-pharmaceuticals/hong-kong-approves-baby-version-biontech-vaccine-toddlers-2022-10-12/" ext-link-type="uri">https://www.reuters.com/business/healthcare-pharmaceuticals/hong-kong-approves-baby-version-biontech-vaccine-toddlers-2022-10-12/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B142-pharmaceutics-15-01349"><label>142.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Measles-Rubella Microarray Patch (MR&#8211;MAP) Target Product Profile. UNICEF</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/330394/9789240000209-eng.pdf" ext-link-type="uri">https://apps.who.int/iris/bitstream/handle/10665/330394/9789240000209-eng.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-01349-f001" orientation="portrait"><label>Figure 1</label><caption><p>Different routes of vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f002" orientation="portrait"><label>Figure 2</label><caption><p>Timeline of Microneedle Research Development.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g002.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f003" orientation="portrait"><label>Figure 3</label><caption><p>Overview of MN types.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g003.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f004" orientation="portrait"><label>Figure 4</label><caption><p>Classification of vaccines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g004.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f005" orientation="portrait"><label>Figure 5</label><caption><p>Cumulative number of publications on microneedles for vaccination. The total number of publications was determined by searching the PubMed database (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/">http://www.ncbi.nlm.nih.gov/pubmed/</uri>) on 15 October 2022, using the search terms &#8220;microneedle for vaccine&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g005.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f006" orientation="portrait"><label>Figure 6</label><caption><p>Structure and infection pathways of SARS-CoV-2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g006.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f007" orientation="portrait"><label>Figure 7</label><caption><p>COVID-19 Vaccines Candidates in Clinical Trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g007.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f008" orientation="portrait"><label>Figure 8</label><caption><p>Classification of COVID-19 vaccines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g008.jpg"/></fig><fig position="float" id="pharmaceutics-15-01349-f009" orientation="portrait"><label>Figure 9</label><caption><p>Cumulative number of publications on microneedles for COVID-19 vaccination. The total number of publications was determined by searching the PubMed database (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/">http://www.ncbi.nlm.nih.gov/pubmed/</uri>) on 15 October 2022, using the search terms &#8220;microneedle COVID-19&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01349-g009.jpg"/></fig><table-wrap position="float" id="pharmaceutics-15-01349-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01349-t001_Table 1</object-id><label>Table 1</label><caption><p>The differences between microneedle delivery of vaccine and traditional injection vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Traditional Injection Vaccines</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MN-Based Vaccines</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Types</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sMN</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cMN</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hMN</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMN</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyd MN</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza [<xref rid="B17-pharmaceutics-15-01349" ref-type="bibr">17</xref>], HBV [<xref rid="B18-pharmaceutics-15-01349" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG [<xref rid="B19-pharmaceutics-15-01349" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 [<xref rid="B20-pharmaceutics-15-01349" ref-type="bibr">20</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ebola <break/>[<xref rid="B21-pharmaceutics-15-01349" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polio <break/>[<xref rid="B22-pharmaceutics-15-01349" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV <break/>[<xref rid="B23-pharmaceutics-15-01349" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovalbumin <break/>[<xref rid="B24-pharmaceutics-15-01349" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sharps injury and contamination</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Have risks</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Needle Breakage Risk</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No risks</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stability</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Refrigerated or frozen</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Depending to the vaccine</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Room temperature</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cold chain</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Need</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Depending to the vaccine</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No need</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccines are injected into the muscle or intradermal multiple times through a syringe</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccines bypassing the stratum corneum and directly into epidermis or dermis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Yes</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Pain-free
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patient compliance</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Non-compliant</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">compliant</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-administration</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Inoperable</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Operable</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-01349-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01349-t002_Table 2</object-id><label>Table 2</label><caption><p>Typical examples for each type of vaccine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Live-attenuated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poliovirus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poliomyelitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-pharmaceutics-15-01349" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chimeric Flavivirus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japanese encephalitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-pharmaceutics-15-01349" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmaceutics-15-01349" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rubella vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rubella virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-15-01349" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycobacterium tuberculosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-pharmaceutics-15-01349" ref-type="bibr">14</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inactive vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatovirus A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-pharmaceutics-15-01349" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-pharmaceutics-15-01349" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-pharmaceutics-15-01349" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudomonas aeruginosa vaccine
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudomonas aeruginosa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-15-01349" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies DNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-01349" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignant melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmaceutics-15-01349" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-pharmaceutics-15-01349" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sars-Cov-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-pharmaceutics-15-01349" ref-type="bibr">68</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Protein vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F1 protein antigen of Yersinia pestis vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plague</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-15-01349" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant subunit Influenza vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmaceutics-15-01349" ref-type="bibr">70</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VLP vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza VLPs vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmaceutics-15-01349" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human papillomavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-15-01349" ref-type="bibr">23</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">toxoid vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetanus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetanus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-pharmaceutics-15-01349" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphtheria vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corynebacterium diphtheriae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-pharmaceutics-15-01349" ref-type="bibr">72</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Measles: Measles is an acute and highly contagious viral disease caused by infection with measles virus. It is common in children and is one of the common acute respiratory infectious diseases in children. Rubella: Rubella is an infection caused by the rubella virus, the main symptom is a rash on the face which spreads to the trunk and extremities. Hepatitis A: Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral hepatitis. Hepatitis B: Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>